

CURRICULUM VITAE

NAME: Julie M. Donohue
BUSINESS ADDRESS: 130 DeSoto Street
Crabtree Hall A635
Pittsburgh, PA 15261
Phone: 412-624-4562
Fax: 412-624-3146
E-mail: jdonohue@pitt.edu

EDUCATION AND TRAINING

Undergraduate

1992-1995	University of Colorado Boulder, CO	BA 1995	Political Science
-----------	---------------------------------------	------------	-------------------

Graduate

1998-2004	Harvard University Cambridge, MA	PhD 2004	Health Policy
-----------	-------------------------------------	-------------	---------------

Post-Graduate

2003-2004	Harvard Medical School Boston, MA Department of Ambulatory Care and Prevention (now Population Medicine)	Post-doctoral fellowship 2004	Pharmaceutical Policy Research
-----------	---	-------------------------------------	-----------------------------------

APPOINTMENTS AND POSITIONS

Academic

2020-	Chair	Health Policy & Management, Graduate School of Public Health, University of Pittsburgh
2017-	Professor	
2011-2017	Associate Professor with tenure	
2014-2020	Vice Chair for Research Assistant Professor	
2004-2011	Assistant Professor	

2014-	Executive Director	Medicaid Research Center, University of Pittsburgh
2013-2020	Co-Director	Center for Pharmaceutical Policy and Prescribing (CP3), University of Pittsburgh
2017-2020	Co-Director	Health services research and policy doctoral program
2004-	Faculty Affiliate	Center for Research on Health Care
Non-Academic		
2015-2018	Member	Advisory Council to Environmental Charter School Counseling Program
2008-	Academic Affiliate	Greylock McKinnon Associates
1997-1998	Public Policy Director	Mental Health Association of Colorado
1996	Staff	Colorado Governor's Commission on National and Community Service

MEMBERSHIP AND LEADERSHIP IN PROFESSIONAL AND SCIENTIFIC ORGANIZATIONS

2021-present	State University Partnership Learning Network, Steering Committee
2014-present	State University Partnership Learning Network, member
2003-present	AcademyHealth, member
2008-2012	American Society of Health Economists, member
2016-2018	Association for Public Policy Analysis and Management, member

HONORS

2014	Craig Award for Excellence in Teaching, Graduate School of Public Health
2013	Delta Omega Honors Society
2010	Finalist for 16 th Annual Health Care Research Award National Institute for Health Care Management
2008	Elected, Secretary and Treasurer of the Health Sciences Section of the Gerontological Society of America
2003	Dissertation accepted with distinction, Harvard University
1998 – 2001	National Institute of Mental Health Training Grant
2000	Derek Bok Teaching Award, Harvard University
1995	Phi Beta Kappa, University of Colorado
1995	Graduated with Distinction, University of Colorado at Boulder

PROFESSIONAL ACTIVITIES

1. Teaching

a. Courses Taught

Years taught	Course Title	Hours, credits, enrollment	Role in course
2019-	HPM 2001: Health Policy and Management in Public Health	3 credit hours, 70 Masters students per year	Primary instructor
2013-present	HPM 3065: Advanced Health Policy Analysis	2 credit hours, 5-6 doctoral students per year	Primary instructor
2006-2016	HPM 2064: Health Policy Analysis	2 credit hours, 15-30 students per year	Primary instructor
2004	HPM 2125: Health Economics	3 credit hours, 5 students	Secondary instructor

b. Other teaching (lectures, tutorials, and continuing education courses)

	Type of teaching	Title
2018	Guest lecture in University of Pittsburgh School of Law	Policy solutions for the opioid crisis
2017-2018	Guest lecture in Undergraduate Seminar in Global Health	Past, Present and Future of the Affordable Care Act
2017-present	Guest lecture in Katz School of Business Executive Program	US Pharmaceutical Prices
2014-present	Guest lecture to HPM 2001 Health Policy and Management	Policy modification
2010-present	Guest lecture for Introduction to Pharmacoepidemiology, Division of Geriatric Medicine	Pharmaceutical promotion, Medicare Part D
2012-present	Guest lecture for 1 st year medical school course on professionalism	Health care reform
2012	Guest lecture Managerial Epidemiology	Working with claims data
2009	Guest lecture for Current Issues in Health Law, University of Pittsburgh School of Law	Health care reform
2008-present	Guest lecture for CLRES 2120: Cost Effectiveness Analysis	Cost-effectiveness and health care policy
2008-2010	Guest lecture for HPM 2105 Health and Medical Care Organization	Pharmaceutical Industry Overview
2008-2010	Guest lecture for BCHS 2526: Health Disparities Research: Methods and Interventions	Health policy approaches to alleviating disparities
2008-2010	Guest lecture for HPM: Health Services Marketing	Advertising in the health care industry
2007	Guest lecture HPM 2125 Health Economics	Pharmaceutical Industry Overview
2007-2010	Guest lecture for Montefiore and Pittsburgh VA Medical Center House Staff	Health Care Reform & Medicare
2005	Guest lecture EPI 2900 Epidemiology of Aging (Cauley, Newman, Strotmeyer)	Suboptimal prescribing in the elderly

c. Major advisor for graduate student essays, theses and dissertations

Name of student	Degree Awarded, Year	Type of document and title
Katherine Appell	MHA, 2021	Master's Essay: "The Role of Medicaid Managed Care in Increasing Permanent Supportive Housing Programs to Address Homelessness"
Elizabeth Croke	MPH, 2021	Master's Essay: "Examination of the effectiveness of web-based interventions that have been developed for informal caregivers of people with dementia: an umbrella review"
Alison Decker	MPH, 2020	Master's Essay: "Economic Impact of <i>Roe v Wade</i> "
Ashley Gallo	MPH, 2019	Master's Essay "Addiction Treatment, Health Policy, and the Criminal Justice System: A Comprehensive Analysis of Access in the United States"
Ashley Narvaez	MHA, 2018	Master's Essay: "Incorporating doula services for better birth outcomes in Medicaid populations"
Winfred Frazier	MPH, 2017	Master's Essay: "Medication-assisted treatment and opioid use response to opioid overdose events"
Kailey Hughes	MPH, 2017	Master's Essay: "Influence of polypharmacy on 30-day readmission rates among Medicare recipients"
Erin Lopata	MPH, 2017	Master's Essay: "Budget impact analysis of Medicaid policy change for hepatitis C treatment"
Katelyn Pontore	MPH, 2015	Master's Essay: "The epidemic of controlled substance diversion related to healthcare professionals"
Lauren Keppel	MPH, 2015	Master's Essay: "Impact of the Affordable Care Act on Preventive Service Use"
Elizabeth Pferdehirt	MPH, 2015	Master's Essay: "Potentially dangerous ingredients in personal care and cosmetic products: A Comparison of US and European Policy"
Phylicia McCalla	MPH, 2014	Master's Essay: "A Movement Toward Health: A Case Study of the Pregnancy Recovery Center"
Samy Ismael	MPH, 2013	Master's Essay: "Introducing wellness programs into the workplace"

Name of student	Degree Awarded, Year	Type of document and title
Nick Malenka	MHA, 2013	Master's Essay: "Evaluating pharmacist-based medication reconciliation: a literature review and case study"
Jessica Ngan	MPH, 2013	Master's Thesis: "Analyzing the Association Between Socioeconomic Factors and Hospital Readmission Rates in California"
Kathleen Slavish	MPH, 2013	Master's Essay: "Emergency Department Utilization among Women with Metastatic Breast Cancer at the End of Life"
Mary Franzen	MPH, 2013	Master's Essay: "Patient-centered care and patient- and family-centered care: definitions and evaluation in selected settings"
Sumaiya Ahmed	MPH, 2012	Master's Essay: "Decreasing healthcare expenditures and improving quality of care in the US through the Alternative Quality Contract"
Zack Papalia	MPH, 2012	Master's Essay: "Inspire Consulting: A Worksite Wellness Company"
Keili Mistovich	MPH, 2012	Master's Essay: "Hospital end-of-life treatment intensity: a comparison of treatment patterns among cancer and non-cancer cohorts"
Carmela Breslin	MPH, 2011	Master's Essay: "Examining the Health Insurance Exchanges Through the Lens of Health Literacy: Is It Truly Consumer Choice?"
Adam Conway	MPH, 2011	Master's Essay: "Integrating Behavioral Health Care Into the Primary Care Setting"
Ashley Hill	MPH, 2011	Master's Essay: "Aligning Value-Based Insurance Design with the Highmark, Inc. Patient Centered Medical Home Pilot"
Lauren McKown	MPH, 2011	Master's Essay: "How Can the McKinney –Vento Act Improve Consistent Access to Health Care for Homeless Children?"
Caitlin Sheetz	MPH, 2011	Master's Essay: "Value Based Purchasing"
Lavi Chimata	MPH, 2010	Master's Essay: "Policy interventions to improve screening for mental health needs in children"
Jennifer Johns	MPH, 2010	Master's Essay: "Policy Analysis of Childhood Obesity"

Name of student	Degree Awarded, Year	Type of document and title
Emily Mahar	MPH, 2010	Master's Essay: "Health reform 2010: Will it bend the cost curve?"
Amy Jones	MPH, 2008	Master's Essay: "Understanding unwarranted geographic variation of end-of-life care in the ICU and how to reduce associated health care spending"
Jennifer Boekeloo	MPH, 2008	Master's Essay: "How much difference does 15 years make? Prospects for National Health Reform in 2008"
Shamika Johnson	MPH, 2008	Master's Essay: "A comparative look at Maine and Massachusetts Health Reform Initiatives"
Carisa Webb	MPH, 2007	Master's Essay: "Employer Mandates: A Practical Approach to Expand Health Insurance Coverage to the Uninsured"
Catherine Acquah	MHA, 2007	Master's Essay: "Employer Mandates: A Practical Approach to Expand Health Insurance Coverage to the Uninsured"
Allison Gaffney	MHA, 2006	Master's Essay: "The effect of the '75% Rule' on Rehabilitation Centers and their patient"
George Mitchell	MHA, 2005	Master's Essay: "Mental Health Parity and Children's Mental Health"
Hsin Ling Tsai	MHA, 2005	Master's Essay: "Consumer characteristics associated with effects of direct-to-consumer advertising"

d. Service on Masters or Doctoral committees

Name of Student	Dates Served	Degree	Title of Dissertation/Essay
Jeremy Adams	2015-2021	PhD	"Cost-effectiveness Analysis of Extended-Release Medications for Opioid Use Disorder: Comparing Single-Drug And Multi-Drug-In-Sequence Treatment Strategies"
Amy Raslevich	2021-	PhD	"How Do Race and Place Affect Disparities in the Utilization of Pediatric Preventive Care Services in Medicaid?"
Ilinca Metes	2014-2020	PhD	"Physician adoption of new prescription drugs: impact on Medicare and Medicaid spending"

Name of Student	Dates Served	Degree	Title of Dissertation/Essay
Tumader Khouja	2015-2020	PhD	“The Oral Health-Systemic Health Connection in Disadvantaged Populations”
Mara Hollander	2015-2020	PhD	“Health and Social Services Utilization Among Vulnerable Populations: Supporting Programs and Policy in Pennsylvania”
Lingshu Xue	2015-2019	PhD	“Long-term effects of diabetes pharmacotherapy on clinical outcomes and economic outcomes”
Carroline Lobo	2014-2017	PhD	“Prescription opioid epidemic in Pennsylvania: Lessons from Medicare and Medicaid”
Kalyani Gopalan	2012-2017	PhD	“Service delivery and quality of care for individuals with mental illness”
Tri Le	2014-2016	PhD	“Inpatient Post-Acute Care Utilization Patterns and Outcomes in Pennsylvania Medicaid”
Yan Tang	2013- 2015	PhD	“Health care system, provider and patient predictors of prescribing quality and efficiency”
Ana Progovac	2013-2015	PhD	“Psychological Attitudes, Health Behaviors, and Healthcare Utilization in the Women's Health Initiative”
Yomei Shaw	2014-2016	PhD	“Decision making about medication therapies for rheumatoid arthritis patients”
Weihsuan Lo-Ciganic	2012-2014	PhD	“Pharmacoepidemiologic Studies: An Interrupted-Time Series Analysis on Drug Utilization and Evaluation of Beneficial or Adverse Drug Effects”
Emily Peron	2012	MS	“Antihypertensive Medication Use in Older Adults: Implications and Appropriateness”
Brian Primack	2009-2011	PhD	“Hookah Tobacco Smoking Among US College Students”
Alexis Blandford	2008	MPH	“Community-based care and services for justice involved individuals with mental illness: the role of federal benefits”
Soma Nikhanj	2009	MPH	“Alleviating urban food deserts: lessons from the literature”

e. Supervision of post-doctoral students, residents and fellows

Dates supervised	Name of trainee	Position
2019-2020	Khadejah Mohamoud, PhD	Post-doctoral fellow
2017-2018	Patience Moyo, PhD	Post-doctoral fellow
2014-2016	Wei-Hsuan Lo-Ciganic, PhD, MSCP, MS	Post-doctoral fellow
• 2016-2017	Natasha Parekh, MD	Post-doctoral fellow
2015-2016	Timothy Anderson, MD	Resident
2016-2017	Winfred Frazier, MD, MPH	Post-doctoral fellow
2015-2016	Philip Rocco, PhD	Post-doctoral fellow
2014-2015	Zachary Marcum, PhD, PharmD, MS	Post-doctoral fellow
2015-2016	Yan Tang, PhD	Post-doctoral fellow
2014-2015	Adeline Gallini, PhD	Post-doctoral fellow

2. Research

Grants and contracts received

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2019-2021	3UL1TR002538-02S1 Develop Infrastructure and Harmonized Metrics to Study the Impact of Opioid ECHO Programs PI: Hess	National Center for Advancing Translational Services (NCATS)	\$7,517	2.5%
2019-2020	840.2019.001 Medicaid Outcomes Distributed Research Network PI: Kennedy	Medicaid and CHIP Payment and Access Commission (MACPAC)	\$38,126	2.5%
2020-2022	State Medicaid Programs and the FDA's Accelerated Approval Pathway PI: Sachs	Laura and John Arnold Foundation	\$15,934	5%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2019-2021	R01DA048019 Examining the quality of opioid use disorder treatment in a Medicaid research network PI: Donohue	NIDA	\$1,158,186	20%
2020-2022	RES 9909 Implementing Prediction Models to Improve Opioid Risk PI: Gellad	Richard King Mellon Foundation	\$358,220	15%
2018-2020	Risk of long-term opioid use and its sequelae due to opioid prescribing for acute pain PI: Donohue	Benter Foundation	\$392,891	5%
2019	Using Section 1115 Demonstration Waivers to Increase Access to Substance Use Disorder Services PI: Cunningham	Robert Wood Johnson Foundation	\$27,362 (sub-contract)	5%
2018-2019	Analyzing State Medicaid Program Efforts to Address Opioid Addiction PI: Cunningham	Kaiser Family Foundation	\$10,000 (sub-contract)	7%
2018-2023	R01DA045675 Accessibility, availability, and structure of opioid use disorder treatment for maternal and child health Multi-PI: Jarlenski/Krans	NIDA	\$471,452	7%
2018-2020	Pennsylvania Opioid Insights PI: Roberts	Pennsylvania Department of Health	\$200,000 (contract)	10%
2018-2019	Machine learning and opioid overdoses Multi-PI: Donohue/Gellad	Richard K. Mellon Foundation	\$446,000	10%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2017-2018	The Effect of the Affordable Care Act Medicaid Expansion on Geographic Access to Safety Net and Acute Care Hospitals PI: Wallace	Robert Wood Johnson Foundation	\$102,284	7%
2017-2020	R01DA044985 Using Machine Learning to Predict Problematic Prescription Opioid Use and Opioid Overdose PI: Gellad	NIDA	\$473,661	4%
2015-2019	R01MD010255 Impacts of Payment Reform on Racial Disparities in Hospital Psychiatric Care PI: Slade	NIMHD	\$21,955 (subcontract)	10%
2015-2019	R01MH107459 Impacts of Payment Models on the Organization of Hospital Care of Persons with Mental Illness PI: Slade	NIMH	\$22,527 (subcontract)	10%
2017-2020	R01MH106682 Improving Value of Publicly Funded Mental Health Care PI: Horvitz-Lennon	NIMH	\$22,087 (subcontract)	10%
2016-2019	R18 HS025072 Enhancing the access and quality of medication-assisted treatment for opioid use disorder in rural PA Medicaid primary care PI: DiDomenico	AHRQ	\$391,335 (subcontract)	5%
2015-2017	Safety of Opioid Use among Veterans Receiving Care in Multiple Health Systems PI: Gellad	US Department of Veterans Affairs	\$19,627 (subcontract)	9%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2016	Developing optimal criteria for identifying overdose of prescription opioids in Pennsylvania Medicare and Medicaid PI: Donohue	GSPH Dean's Pilot Grant Program	\$25,000	0%
2014-2019	Pennsylvania Medicaid Research and Analysis PI: James	Pennsylvania Department of Human Services	\$2,000,000 (contract)	20%
2014-2016	U01CE002496 The influence of formulary management strategies on opioid medication use among patients and prescribers Multi-PI: Cochran/Donohue	CDC	\$199,949	10%
2014-2018	R01MH10056 Dialectical Behavioral Therapy for Adolescents with Bipolar Disorder PI: Goldstein	NIMH	\$16,052 (subcontract)	5%
2013-2018	R01HL119246 The Role of physician networks in the adoption of new drugs PI: Donohue	NHLBI	\$575,000	35%
2013-2016	R01AG028050 Peripheral nerve decline: an underappreciated cause of injurious falls PI: Strotmeyer	NIA	\$28,041 (subcontract)	10%
2013-2016	R01DA035214 Substance use disorder treatment under new payment and delivery system models Multi-PI: Huskamp/Barry	NIDA	\$36,506 (subcontract)	20%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2012-2015	R01MH093359 Influences on Psychiatrist Prescribing of Antipsychotics Multi-PI: Donohue/Huskamp	NIMH	\$447,659	30%
2009-2012	R01HS017695 Impact of Medicare Part D on Racial Disparities in Diabetes Treatment and Outcomes PI: Donohue	AHRQ	\$122,086	25%
2010-2013	R01MH087488 An In-Depth Investigation of Racial & Ethnic Disparities in Schizophrenia Care PI: Horvitz-Lennon	NIMH	\$6,497 (subcontract)	5%
2012-2013	Administrative Supplement to R01 MH087488	NIMH	\$56,157 (subcontract)	10%
2011-2016	P30MH090333 Advanced Center for Late Life Mood Disorders PI: Reynolds	NIMH	\$6,800	5%
2010-2015	U48DP001918-01 Health Promotion and Disease Prevention Research Center PI: Newman	CDC	\$14,000	10%
2006-2010	KL2RR024154-04 Medicare Beneficiaries and High Cost Pharmaceuticals Role: Scholar	NIH, NCRR	\$120,839	75%
2011-2012	Health system predictors of generic drug use and consequences for out-of-pocket costs and medication adherence in Medicare Part D PI: Donohue/Gellad	RAND University of Pittsburgh Health Initiative	\$35,000	5%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
2011	Cost Effectiveness of depression treatment following coronary artery bypass graft surgery PI: Donohue	Fine Foundation	\$35,000	5%
2008-2010	R34MH082682 Medicare Part D Cost-sharing and Treatment of Mental Disorders among Disabled Dually Eligible Beneficiaries PI: Donohue	NIMH	\$125,000	40%
2006-2010	R01HL070000 Treatment of Depression Following Bypass Surgery PI: Rollman	NHLBI	\$20,144 (subproject)	1% contributed
2009-2011	R01AG034056 Racial Disparities in Older Adults: Impact of Medicare part D PI: Hanlon	NIA	\$150,000	20%
2005-2007	<i>Consumers Union</i> Consumer Reports Best Buy Drug Program PI of sub-contract	Massachusetts General Hospital	\$9,714	20%
2004-2006	The Impact of Medicaid Prior Authorization Policies for Antidepressants on Medication Choice PI: Donohue	Pilot Grant, Department of Psychiatry, University of Pittsburgh Medical School	\$13,193	10%
2005	Medication Use and Cost for the Dually Eligible Under MMA PI: Frank	NIMH Professional Services Contract	\$8,300	7.5%

PUBLICATIONS

1. Peer reviewed

1. Medicaid Outcomes Distributed Research Network (MODRN), **Donohue JM**, Jarlenski MP, Kim JY, et al. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. *JAMA*. 2021 Jul 13;326(2):154-164. doi: 10.1001/jama.2021.7374. PMID: 34255008.
2. Drake C, Nagy D, Nguyen T, Kraemer KL, Mair C, Wallace D, **Donohue, JM**. A comparison of methods for measuring special access to health care. *Health Services Research* July 2021 <https://doi.org/10.1111/1475-6773.13700>
3. Horvitz-Lennon M, Volya R, Hollands S, Zelevinsky K, Mulcahy A, **Donohue JM**, Normand SLT. Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults. *Psychiatric Services* 2021 (in press)
4. Horvitz-Lennon M, Volya R, Zelevinsky K, Shen M, **Donohue JM**, Mulcahy A, Normand SLT. Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults. *Administration and Policy in Mental Health and Mental Health Services Research* 2021 (in press).
5. Roberts ET, Glynn A, Cornelio N, **Donohue JM**, Gellad WF, McWilliams JM, Sabik LM. Medicaid Coverage ‘Cliff’ Increases Expenses And Decreases Care For Near-Poor Medicare Beneficiaries: Study examines near-poor Medicare beneficiaries access to supplemental coverage and the impact on their out-of-pocket expenses and use of health care. *Health Affairs* 2021 (in press).
6. Lo-Ciganic WH, **Donohue JM**, Hulsey EG, Barnes S, Li Y, Kuza CC, Yang Q, Buchanich J, Huang JL, Mair C, Wilson DL, Gellad WF. Integrating human services and criminal justice data with claims data to predict risk of opioid overdose among Medicaid beneficiaries: A machine-learning approach *PloS One* 2021 (in press).
7. Marin JR, Hollander MAG, Ray KN, **Donohue JM**, Cole ES. Low-Value diagnostic imaging in children with Medicaid. *The Journal of Pediatrics*. 2021 (in press).
8. Gu C, Huskamp H, Donohue JM, Normand SLT. A Bayesian hierarchical model for characterizing the diffusion of new antipsychotic drugs *Biometrics* 2021 (in press)
9. Cochran G, Cole ES, Sharbaugh M, Nagy D, Gordon AJ, Gellad WF, Pringle J, Bear T, Warwick J, Drake C, Chang CCH, DiDomenico E, Kelley D, **Donohue JM**. Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder. *Journal of Addiction Medicine* doi: 10.1097/ADM.0000000000000859
10. Wilson JD, Abebe KZ, Kraemer K, Liebschutz J, Merlin J, Miller E, Kelley D, **Donohue JM**. Trajectories of opioid use following first opioid prescriptions in opioid-naïve youths and young adults. *JAMA Network Open* 2021;4(4):e214552. doi:10.1001/jamanetworkopen.2021.4552
11. Jarlenski M, Kim JY, Ahrens KA, Allen L, Austin A, Barnes AJ, Crane D, Lanier P, Mauk R, Mohamoud S, Pauly N, Talbert J, Zivin K, **Donohue JM**. Healthcare patterns of pregnant women and children affected by OUD in 9 state Medicaid populations. *Journal of Addiction Medicine* 2021 Feb 5. doi: 10.1097/ADM.0000000000000780

12. Cole ES, **Donohue JM** et. al. Patterns of Clinic Switching and Continuity of Medication for Opioid Use Disorder in a Medicaid-Enrolled Population. *Drug and Alcohol Dependence*. Feb. 2020. Ms. Ref. No. KE-20-0732R1 (in press).
13. Marin JR, Hollander M, Ray KN, **Donohue JM**, Cole ES. Low-Value Diagnostic Imaging in Children with Medicaid. *Journal of Pediatrics* 2021 (in press)
14. Hollander MAG, Chang Chung-Chou H, Cole ES, **Donohue JM**, Jarlenski, MP, Kahn JM, Sabik LM, Emergency Department and Ambulatory Care Visits in the First 12 Months of Coverage Under Medicaid Expansion: A Group-Based Trajectory Analysis. *Annals of Internal Medicine*, 2020, January 2021 (in press).
15. Hollander MAG, Cole E, **Donohue, JM**, Roberts E. Changes in Medication Utilization and Spending Associated with Homeless Adults' Entry into Permanent Supportive Housing. *J Gen Intern Med*. 2020 (in press).
16. Roberts ET, Glynn A, **Donohue JM**, Sabik LM. The Relationship Between Take-up of Prescription Drug Subsidies and Medicaid Among Low-Income Medicare Beneficiaries. *J Gen Intern Med*. 2020 Sep 21;. doi: 10.1007/s11606-020-06241-y. [Epub ahead of print] PubMed PMID: 32959349.
17. Guo J, Lo-Ciganic WH, Yang Q, Huang JL, Weiss JC, Cochran G, Malone DC, Kuza CC, Gordon AJ, **Donohue JM**, Gellad WF. Predicting Mortality Risk after a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. *Journal of General Internal Medicine*
18. Moyo P, **Donohue JM**. Commentary on Zhou et al (2020): Policy levers to reduce co-prescribing of opioids and gapapentinoids and overdose risk. *Addiction* <https://doi.org/10.1111/add.15308>
19. Wallace JD, **Donohue JM**, Angus DC, Sabik LM, Davis B, Yabes J, Kahn JM. Association between state Medicaid expansion and Emergency Access to Acute Care Hospitals in the United States. *JAMA Network Open* 2020. doi:[10.1001/jamanetworkopen.2020.25815](https://doi.org/10.1001/jamanetworkopen.2020.25815)
20. Xue L, Strotmeyer ES, Zgibor J, Costacou T, Boudreau R, Kelley D, **Donohue JM**. Cardiovascular disease risk and the time to insulin initiation for Medicaid enrollees with type 2 diabetes *Journal of Clinical & Translational Endocrinology* (2020).
21. Sachs RE, **Donohue JM**, Duzetzina SB. Confronting State Medicaid Drug Spending Pressures. *JAMA* 2020;324(18):1831-1832. doi:10.1001/jama. 2020.19325
22. **Donohue JM**, Miller E. COVID-19 and School Closures. *JAMA* 2020 Jul 29. doi: 10.1001/jama.2020.13092
23. Drake C, **Donohue JM**, Nagy D, Mair C, Kraemer KL, Wallace DJ. Geographic access to buprenorphine prescribers for patients who use public transit. *Journal of Substance Abuse Treatment* 2020 Oct;117:108093. doi: 10.1016/j.jsat.2020.108093
24. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Kwok CK, **Donohue JM**, Gordon AJ, Cochran G, Malone DC, Kuza CC, Gellad WF. Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: a prognostic study. *PLoS One* 2020 Jul 17;15(7):e0235981. doi: 10.1371/journal.pone.0235981.
25. Khouja T, Burgette J, **Donohue JM**, Roberts E. Association Between Medicaid Expansion, Dental Coverage Policies for Adults and Children's Receipt of Preventive Dental Services. *Health Services Research*, 2020 (in press)
26. Germack HD, Drake C, **Donohue JM**, Golberstein E, Busch S. National trends in outpatient mental health service use between 2008 and 2015. *Psychiatric Services*, 2020 (in press)

27. Gu C., Huskamp H.A., **Donohue J.M.**, Normand S.L. A Bayesian Hierarchical Model for Characterizing the Diffusion of New Antipsychotic Drugs. *Biometrics*. 2020 (in press) <https://doi.org/10.1111/biom.13324>
28. Hernandez I., Hershey T.B., **Donohue J.M.** Drug shortages in the United States: Are Some Prices Too Low? *JAMA* 323(9): 819-820, 2020.
29. Jarlenski M.P., Krans E.E., Kim J.Y., **Donohue J.M.**, James A.E. 3rd, Kelley D., Stein B.D., Bogen D.L. Five-Year Outcomes Among Medicaid-Enrolled Children with In-Utero Opioid Exposure. *Health Affairs* 39(2): 247-255, 2020.
30. Hollander M.A.G, **Donohue, J.M.**, Stein B.D., Krans E.E., Jarlenski M. Association between opioid prescribing in Medicare and pharmaceutical company gifts by physician specialty. *Journal of General Internal Medicine* 2020 Aug;35(8):2451-2458
31. Adams L., Kennedy S., Allen L., Barnes A., Bias T., Crane D., Lanier P., Mauk R., Mohamoud S., Pauly N., Talbert J., Woodcock C., Zivin K., **Donohue J.M.** Innovative solutions for state Medicaid programs to leverage their data, build their analytic capacity, and create evidence-based policy. *EGEMS* 7(1): 41, 1-6. 2019
32. Metes I.D., Xue L., Chang C.C-H., Huskamp H.A., Gellad W.F., Lo-Ciganic W-H, Choudhry N.K., Richards-Shubik S., Glucu H., **Donohue J.M.** Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending. *BMC Health Services Research*. Oct 19(1): 703, 2019.
33. Lobo C., Cochran G., Chang C.H., Gellad W.F., Gordon A.J., Jalal H., Lo-Ciganic W-H, Karp J.F., Kelley D., **Donohue J.M.** Associations between the specialty of opioid prescribers and opioid addiction, misuse, and overdose outcomes. *Pain Medicine*. Oct 2019.
34. Cochran G., Cole E.S., Warwick J., **Donohue J.M.**, Gordon A.J., Gellad W.F., Bear T., Kelley D., DiDomenico E., Pringle J. Rural Access to MAT in Pennsylvania (RAMP): A Hybrid Implementation Study Protocol for Medication Assisted Treatment Adoption among Rural Primary Care Providers. *Addict Sci Clin Pract*. 14 (25) Aug 2019
35. Moyo P., Gellad W.F., Sabik L.M., Cochran G.T., Cole E.S., Gordon A.J., Kelley D., **Donohue J.M.** Prevalence of Prescription Opioid Use Quality Measures among Pennsylvania Medicaid Enrollees with and without Cancer. *Am J Prev Med* 2019 Oct;57(4):540-544.
36. Roberts E.T., Hayley Welsh J., **Donohue J.M.**, Sabik L.M. Association Of State Policies with Medicaid Disenrollment Among Low-Income Medicare Beneficiaries. *Health Aff (Millwood)*. 2019 Jul;38(7):1153-1162.
37. **Donohue J.M.**, Kennedy J., Seymour C.W., Girard T.D., Lo-Ciganic W-H., Kim C.H., Marroquin O.C., Moyo P., Chang C.C., Angus D.C. Patterns of Opioid Administration During Inpatient Stays and Associations with Post-discharge Opioid Use: A Cohort Study of previously opioid-naïve patients. *Annals of Internal Medicine*. 2019 Jul 16;171(2):81-90
38. Progovac A.M., Pettinger M., **Donohue J.M.**, Chang C.C., Matthews K.A., Habermann E.B., Kuller L., Rosal M., Li W., Garcia L., Tindle H.A. Optimism may moderate screening mammography frequency in Medicare: A longitudinal study. *Medicine*. 2019 Jun;98(24):e15869.
39. Cole E.S., DiDomenico E., Cochran G., Gordon A.J., Gellad W.F., Pringle J., Warwick J., Chang C.C.H., Kim J.Y., Kelley D., **Donohue J.M.** The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. *Journal of General Internal Medicine*. 2019 Jun;34(6):936-943.

40. Lo-Ciganic W., Huang J.L., Zhang H.H., Weiss J.C., Wu Y., Kwoh C.K., **Donohue J.M.**, Cochran G., Gordon A.J., Malone D.C., Kuza C.C., Gellad W.F. Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. *JAMA Network Open*, 2019;2(3):e190968. DOI:10.1001/jamanetworkopen.2019.0968.
41. Hollander M.A.G., Jarlenski M.P., **Donohue J.M.**, Cole E.S., Kelley D., Krans E.E. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder. *American Journal of Obstetrics and Gynecology*. 2019 May;220(5):502-503.
42. Moyo P., Zhao X., Thorpe C.T., Thorpe J.M., Sileanu F.E., Cashy J.P., Hale J.A., Mor M.K., Radomski T.R., **Donohue J.M.**, Hausmann L.R.M., Hanlon J.T., Good C.B., Fine M.J., Gellad W.F. Patterns of Opioid Prescriptions Received Prior to Unintentional Prescription Opioid Overdose Death among Veterans. *Research in Social and Administrative Pharmacy*. 2018 Oct 17. pii: S1551-7411(18)30282-1. doi: 10.1016/j.sapharm.2018.10.023. [Epub ahead of print]
43. Radomski TR, Zhao X, Hanlon JT, Thorpe JM, Thorpe CT, Naples JG, Sileanu FE, Cashy JP, Hale JA, Mor MK, Hausmann LRM, **Donohue JM**, Suda KJ, Stroupe KT, Good CB, Fine MJ, Gellad WF. Use of a medication-based risk adjustment index to predict mortality among veterans dually-enrolled in VA and Medicare. *Healthcare (Amst)*. 2019 Apr 25. pii: S2213-0764(18)30230-6. doi: 10.1016/j.hjdsi.2019.04.003. [Epub ahead of print].
44. Moyo P, Zhao X, Thorpe CT, Thorpe JM, Sileanu FE, Cashy JP, Hale JA, Mor MK, Radomski TR, **Donohue JM**, Hausmann LRM, Hanlon JT, Good CB, Fine MJ, Gellad WF. Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans: A Nested Case-Control Study. *Annals of Internal Med*. 2019 Mar 12. doi: 10.7326/M18-2574. [Epub ahead of print]
45. Carico R, Zhao X, Thorpe CT, Thorpe JM, Sileanu FE, Cashy JP, Hale JA, Mor MK, Radomski TR, Hausmann LRM, **Donohue JM**, Suda KJ, Stroupe K, Hanlon JT, Good CB, Fine MJ, Gellad WF. Receipt of overlapping opioid and benzodiazepine prescriptions among veterans dually enrolled in Medicare Part D and the Department of Veterans Affairs: A Cross-Sectional Study. *Annals of Internal Medicine*. 2018 Nov 6;169(9): 593-601.
46. **Donohue J.M.**, Guclu H., Gellad W.F., Chang C-C.H., Huskamp H.A., Choudhry N.K., Zhang R., Lo-Ciganic W-H., Junker S.P., Anderson T., Richards-Shubik S. Influence of peer networks on physician adoption of new drugs. *PLOS ONE*. 2018 Oct 1;13(10):e0204826.
47. Lo-Ciganic W-H, **Donohue J.M.**, Kim J.Y, Krans E.E., Jones B.L., Kelley D., James A.E., Jarlenski M.P. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. *Pharmacoepidemiology and Drug Safety*. 2019 Jan;28(1):80-89.
48. Gopalan K., Horvitz-Lennon M., Stein B.D., Ghinassi F., Castle N., Chang C-C., **Donohue J.M.**, Is mental illness a risk factor for hospital 30-day readmission? *Administration and Policy in Mental Health and Mental Health Services Research*. 2018 Nov;45(6):933-943.
49. **Donohue, J.M.**, Huskamp, H.A. Doughnuts and discounts – changes to Medicare Part D under the Bipartisan Budget Act of 2018. *New England Journal of Medicine*. 2018 May 24;378(21):1957-1960.
50. Cochran G., Lo-Ciganic W-H., Gellad W.F., Gordon A.J., Cole E., Lobo C., Frazier W., Zheng P., Kelley D., & **Donohue J.M.** Prescription Opioid Quality Measures Applied among

- Pennsylvania Medicaid Enrollees. *Journal of Managed Care & Specialty Pharmacy*. 2018 Sep;24(9):875-885.
51. Parekh N., **Donohue J.M.**, Corbelli J., Men A., Kelley D., Jarlenski M. Screening for Sexually Transmitted Infections after Cervical Cancer Screening Guideline and Medicaid Policy Changes: A Population-Based Analysis. *Medical Care*. 2018 Jul;56(7):561-568.
 52. Gellad W.F., Thorpe J.M., Zhao X., Thorpe C.T., Sileanu F.E., Cashy J.P., Hale J.A., Mor M.K., Radomski T.R., Hausmann L.R.M., **Donohue J.M.**, Gordon A.J., Suda K.J., Stroupe K.T., Hanlon J.T., Cunningham F.E., Good C.B., Fine M.J. Impact of dual use of Department of Veterans Affairs and Medicare Part D drug benefits on potentially unsafe opioid use. *American Journal of Public Health* 2018 Feb;108(2):248-255.
 53. Progovac A.M., **Donohue J.M.**, Matthews K.A., Chang C-C., Habermann E.B., Kuller L.H., Saquib J., LaMonte M.J., Salmoirago-Blotcher E., Zaslavsky O., Tindle H.A. Optimism predicts sustained vigorous physical activity in postmenopausal women. *Preventive Medicine Reports*. 2017 Oct 16;8: 286-293.
 54. Anderson T.S., Lo-Ciganic W.H., Gellad W.F., Zhang R., Huskamp H.A., Choudhry N.K., Chang C.C.H., Richards-Shubik S., Guclu H., Jones B., **Donohue J.M.** Patterns and predictors of physician adoption of new cardiovascular drugs. *Healthcare: The Journal of Delivery Science and Innovation*. 2018 Mar;6(1):33-40.
 55. **Donohue J.M.**, Barry C.L., Stuart E.A., Greenfield S.F., Song Z., Chernew M.E., Huskamp H.A. Effects of global payment and accountable care on medication treatment for alcohol and opioid use disorders. *Journal of Addiction Medicine* 2018 Jan/Feb;12(1):11-18.
 56. Koma, J.W., **Donohue, J.M.**, Barry, C.L., Huskamp, H.A., Jarlenski, M.P. Medicaid coverage expansions and cigarette smoking cessation among low-income adults. *Medical Care*. 2017 Dec;55(12):1023-1029.
 57. Joyce N.R., Huskamp H.A., Hadland S., **Donohue J.M.**, Greenfield S.F., Stuart E.A., Barry C.L. Did the Alternative Quality Contract Impact Service Use and Spending for Children with ADHD? *Psychiatric Services*, 2017 Dec 1;68(12):1210-1212.
 58. Mulcahy, A.M., Normand, S.L.T., Newcomer, J., Colaiaco, B., **Donohue, J.M.**, Horvitz-Lennon, M. Simulated effects of policies to reduce diabetes risk among adults with schizophrenia receiving antipsychotics. *Psychiatric Services*. 2017 Dec 1;68(12):1280-1287.
 59. Parekh, N.K., **Donohue, J.M.**, Men, A., Corbelli, J., Jarlenski, M. Rethinking how to measure the appropriateness of cervical center screening. *Annals Internal Medicine*. 2017 Sep 19;167(6):445-446.
 60. Frazier W., Cochran G., Lo-Ciganic W.H., Gellad W.F., Gordon A.J., Chang C.C., **Donohue J.M.** Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid *JAMA* 2017;318(8):750-752
 61. Shaw, Y., Metes, I., Michaud, K., **Donohue, J.M.**, Roberts, M., Levesque, M., Chang, J. Rheumatoid arthritis patients' motivations for accepting or resisting disease modifying anti-rheumatic drug treatment regimens. *Arthritis Care & Research*. 2018 Apr;70(4):533-541.
 62. Shaw, Y., Chang C.H., Levesque, M., **Donohue, J.M.**, Michaud, K., Roberts, M. Timing and impact of decisions to adjust disease-modifying antirheumatic drug therapy for rheumatoid arthritis patients with active disease. *Arthritis Care Res*. 2018 Jun;70(6):834-841.

63. Tang, Y., Horvitz-Lennon, M., Gellad, W. F., Lave, J. R., Chang, C.C., Normand, S.L.T., & **Donohue, J. M.** Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large Medicaid program. *Psychiatric Services*. 2017 Jun 1; 68(6): 579-586.
64. Cochran, G., Gordon, A.J., Gellad, W., Chang, C-C., Lo-Ciganic, W-H., Cole., E., Frazier, W., Zheng, P., Kelley, D., & **Donohue, J.M.** Medicaid prior authorization and opioid medication abuse and overdose. *American Journal of Managed Care*. 2017 May 1;23(5):e164-e171.
65. **Donohue J.M.**, Angus D.C. National shortages of generic sterile injectable drugs: norepinephrine as a case study of potential harm. *JAMA*. 2017 Apr 11;317(14):1415-1417.
66. Hanlon JT, Perera S, Newman AB, Thorpe JM, **Donohue J.M**, Simonsick EM, Shorr RI, Bauer DC, Marcum ZA; Health ABC Study. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. *Journal of Clinical Pharmacy and Therapeutics*. 2017 Apr;42(2):228-233.
67. Cochran G., Gordon AJ., Lo-Ciganic W., Gellad W., Frazier W., Lobo C., Chang J., Zheng P., **Donohue J.M.** An examination of claims-based predictors of overdose from a large Medicaid program. *Medical Care*. 2017 Mar;55(3):291-298.
68. Progovac A.M., Chang Y.F., Chang C.-C.H. Matthews K.A., **Donohue, J.M.**, et al. Are optimism and cynical hostility associated with smoking cessation in older women? *Annals of Behavioral Medicine*. 2017 Aug;51(4):500-510.
69. Jarlenski M., Bodnar L.M., Kim J.Y., **Donohue J.M.**, Krans E.E., Bogen D.L. Filled opioid prescription after vaginal delivery in Medicaid *Obstetrics & Gynecology* 2017 Mar;129(3):431-437
70. Parekh N., **Donohue JM**, Men A, Corbelli J, Jarlenski M. Cervical Cancer Screening Guideline Adherence Before and After Guideline Changes in Pennsylvania Medicaid. *Obstetrics & Gynecology*. 2017 Jan;129(1):66-75.
71. Jarlenski M, Rocco P, Tipirneni, Kennedy AJ, Guntari N, **Donohue JM**. Shaping health policy for low-income populations: An assessment of public comments in a new Medicaid waiver process. *Journal of Health Politics, Policy and Law*. 2017 Dec;42(6):1039-1064.
72. Stuart E.A., Barry C.L., **Donohue J.M.**, Greenfield S.F., Duckworth K., Song Z., Kouri E.M., Ebnesajjad C., Mechanic R., Chernew M.E., and Huskamp H.A. Effects of accountable care and payment reform on substance use disorder treatment: Evidence from the initial three years of the Alternative Quality Contract. *Addiction*. 2017 Jan;112(1):124-133.
73. Huskamp HA, Horvitz-Lennon M, Berndt ER, Normand ST, **Donohue JM**. Patterns of antipsychotic prescribing by physicians to young children. *Psychiatric Services*. 2016 Dec 1;67(12):1307-1314.
74. Kabiri M., Chhatwal J., **Donohue J.M.**, Roberts M.S., James A.E., Dunn M.A., Gellad W.F. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. *Healthcare*. 2016 Dec 5. pii: S2213-0764(16)30214-7.
75. Chhatwal J., Wang X., Ayer T., Kabiri M., Chung R.T., Hur C., **Donohue J.M.**, Roberts M.S., Kanwal F. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. *Hepatology*. 2016 Nov;64(5):1442-1450.
76. Huskamp H.A., Greenfield S.F., Stuart E.A., **Donohue, J.M.**, Duckworth K., Kouri E., Song Z., Chernew M.E., Barry C.L. Effects of global payment and accountable care on tobacco

- cessation service use: an observational study. *Journal of General Internal Medicine*. 2016 Oct;31(10):1134-40.
77. Lo-Ciganic W, **Donohue JM**, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, Gellad WF. Trajectories of Diabetes Medication Adherence and Hospitalization Risk. *Journal of General Internal Medicine*. 2016 Sep;31(9):1052-60.
 78. Vater L.B., **Donohue, J.M.**, Park S.Y., Schenker Y. Trends in cancer center spending on advertising in the United States, 2005-2014. *JAMA Internal Medicine*. 2016 Aug 1;176(8):1214-6.
 79. Lo-Ciganic W, Gellad WF, Huskamp HA, Choudhry NK, Chang CH, Zhang R, Jones BL, Guclu H, Richards-Shubik S, **Donohue J.M.** Who Were the Early Adopters of Dabigatran? An Application of Group-Based Trajectory Models. *Medical Care*. 2016 Jul;54(7):725-32.
 80. Marcum Z., Bellon J., Li J., Gellad W.F., **Donohue J.M.** New Chronic Disease Medication Prescribing by Nurse Practitioners, Physician Assistants, and Primary Care Physicians: A Cohort Study. *BMC Health Services Research*. 2016 Jul 27;16:312.
 81. Chidi A.P., Bryce C.L. **Donohue J.M.**, Fine M.J., Landsittel D., Myaskovsky L., Rogal S., Switzer G., Tsung A., Smith K. Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients. *Value in Health*. 2016 Jun;19(4):326-34.
 82. **Donohue JM**, Normand S-LT, Horvitz-Lennon M, Men A, Berndt ER, Huskamp HA. Regional variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures. *The Journal of Mental Health Policy and Economics*. 2016 Jun;19(2):69-78.
 83. Gordon A, Lo-Ciganic W-H, Cochran G, Gellad WF, Cathers T, **Donohue JM**. Treatment quality for buprenorphine care: the pot at the end of the rainbow. *Journal of Addiction Medicine*. 2016 May-Jun;10(3):210-1.
 84. Lo-Ciganic W-H., Gellad W.F., Gordon A.J., Cochran G., Zemaitis M.A., Cathers T., Kelley D., **Donohue J.M.** Associations between Trajectories of Buprenorphine Treatment and Emergency Department and Inpatient Utilization. *Addiction*. 2016 May;111(5):892-902.
 85. Tang Y., Chang C-C., Lave J.R., Gellad W.F., Huskamp H.A., **Donohue J.M.** Patient, physician and organizational influences on variation in prescribing behavior: evidence from antipsychotic medications in a large Medicaid program. *Journal of Mental Health Policy and Economics*. 2016 Mar;19(1):45-59.
 86. Barry C.L., Stuart E.A., **Donohue J.M.**, Greenfield S.F., Kouri E.M., Duckworth K., Song Z., Mechanic R., Chernew M.E., Huskamp H.A., The Early Impact of the “Alternative Quality Contract” on Mental Health Service Use and Spending in Massachusetts. *Health Affairs*. 2015 Dec;34(12):2077-85.
 87. Conroy M.B., Zgibor J.C, Simkin-Silverman L., **Donohue J.M.**, Albert S.M., Kuller LH, Newman AB. Bundling Preventive Services for Community-Dwelling Seniors: Rationale for Multi-faceted Public Health Interventions. *Primary Health Care* 5: 203, 2015.
 88. Gordon A.J., Lo-Ciganic, W-H. Cochran G., Gellad W.F., Cathers T., Kelley D., **Donohue J.M.** Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. *Journal of Addiction Medicine*. 2015 Nov-Dec;9(6):470-7.
 89. Rocco P., Gellad W.F., **Donohue J.M.** Modernizing Medicaid Managed Care: Can States Meet the Data Challenges? *JAMA*. 2015 Oct 20;314(15):1559-1560.
 90. **Donohue J.M.**, Papademetriou E., Henderson R.R., Frazee S.G., Eibner C., Mulcahy A.W., Mehrotra A., Bharill S., Cui C., Stein B.D., Gellad W.F. Early Marketplace Enrollees Were

- Older And Used More Medication Than Later Enrollees; Marketplaces pooled risk. *Health Affairs*. 2015 June; 34(6): 1049-56.
91. Anderson T.S., Huskamp H.A., Epstein A.J., Barry C.L., Men A., Berndt E.R., Horvitz-Lennon M., Normand S.L.T., **Donohue J.M.** Antipsychotic Prescribing: Do conflict of interest policies make a difference? *Medical Care*. April 53(4):338-45, 2015.
 92. Lo-Ciganic W., **Donohue J.M.**, Thorpe J.M., Perera S., Thorpe C.T., Marcum Z.A., Gellad W.F. Using Machine Learning to Examine Medication Adherence Thresholds and Risk of Hospitalization. *Medical Care*. 2015 Aug; 53(8): 720-8.
 93. Gallini A, Gardette V, Oumouhou N, Andrieu S, **Donohue JM**. Evolution of general practitioners' preferences for antipsychotics in France, 2003-2010. *Psychiatric Services* April 1 66(4): 434-437, 2015.
 94. Horvitz-Lennon, M., Volya, R., Garfield, R., **Donohue, J.M.**, Lave, J.R., Normand, S.L.T. Where you live matters: Quality and racial/ethnic disparities in the care of schizophrenia in four state Medicaid programs. *Health Services Research*. 2015 Oct; 50(5): 1710-29.
 95. Cochran, G., Woo, B., Lo-Ciganic, W., Gordon, A., **Donohue, J.M.**, and Gellad, W.F. Defining non-medical use of prescription opioids within health care claims: A systematic review. *Substance Abuse*, Apr-Jun; 36(2): 192-202, 2015.
 96. Bao Y, Tang Y, **Donohue, J.M.** Retaining Part D's comprehensive coverage of antidepressants: not a silver bullet. *JAMA Psychiatry* 72(3): 201-202, 2015.
 97. Lo-Ciganic W., Perera S., Gray S.L., Boudreau R.M., Zgibor J.C., Strotmeyer E.S., **Donohue J.M.**, Bunker C.H., Newman A.B., Simonsick E.M., Bauer D.C., Satterfield S., Caserotti P., Harris T., Shorr R.I., Hanlon J.T. Statin Use and Gait-Speed Decline in Community-Dwelling Older Adults. *Journal of American Geriatrics Society* Jan; .63(1):124-9, 2015.
 98. Marcum Z.A., Driessen J., Thorpe C.T., **Donohue, J.M.**, Gellad W.F. Regional variation in use of a new class of antidiabetic medication among Medicare beneficiaries: the case of incretin mimetics. *Annals of Pharmacotherapy* 2015 March 49(3):285-92.
 99. Marcum Z.A., Hanlon J.T., Strotmeyer E.S., Newman A.B., Shorr R.I., Simonsick E.M., Bauer D.C., Boudreau R., **Donohue J.M.**, Perera S., for the Health ABC Study. Gastroprotective agent underuse in high-risk older daily non-steroidal anti-inflammatory drug users over time. *Journal of American Geriatrics Society* 2014 Oct;62(10):1923-7.
 100. **Donohue J.M.**, Belnap B.H., Men A., He F., Roberts M.S., Schulberg H.C., Reynolds III C.F., Rollman B.L. 12-month cost-effectiveness of telephone delivered collaborative care for treating depression following CABG surgery: a randomized controlled trial. *General Hospital Psychiatry* 2014 Sept-Oct;36(5):453-9.
 101. **Donohue, J.M.** Impact and evolution of Medicare Part D. *New England Journal of Medicine* 2014 Aug 21; 371(8): 693-5.
 102. Gellad W.F., Stein B.D., Ruder T., Henderson R., Frazee S.G., Mehrotra A., **Donohue J.M.** Geographic variation in receipt of psychotherapy in children receiving attention-deficit/hyperactivity disorder medications. *JAMA Pediatrics* November 168(11): 1074-6, 2014.
 103. Vater L.B., **Donohue J.M.**, Arnold R.M., White D.B., Chu E., Schenker Y. What are cancer centers advertising to the public? A content analysis. *Annals of Internal Medicine* 2014 June 17;160(12):813-20
 104. Tang Y., Gellad W.F., Men A., **Donohue J.M.** Impact of Medicare Part D plan features on

- use of generic drugs. *Medical Care* 2014 Jun;52(6):541-8.
105. Horvitz-Lennon M., **Donohue J.M.**, Lave J.R., Stein B.D. Normand S.L. Disparities in Quality of Care among Publicly Insured Adults with Schizophrenia in Four Large US States, 2002-2008. *Health Services Research* 2014 Mar; 49(4):1121-1144.
 106. Marcum Z., Driessen J., Thorpe C., Gellad W., **Donohue J.M.** Impact of multiple pharmacy use on medication adherence and drug-drug interactions in older adults with Medicare Part D. *Journal of the American Geriatrics Association* 2014 Feb;62(2):244-52.
 107. **Donohue J.M.**, O'Malley A.J., Horvitz-Lennon M., Levine Taub A., Berndt E.R., Huskamp H.A. Changes in physician antipsychotic prescribing preferences 2002-2007. *Psychiatric Services* 2014 Mar 1;65(3):315-22.
 108. Gallini A, Andrieu S, **Donohue J.M.**, Oumouhou N, Lapeyre-Mestre M. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. *European Neuropsychopharmacology* 2014 Jan;24(1):95-104.
 109. Hanlon J.T., Boudreau R.M., Perera S., Strotmeyer E.S., Newman A.B., Simonsick E.M., Shorr R.I., Bauer D.C., **Donohue J.M.** for the Health ABC Study. Racial Differences in Antilipemic Use and Lipid Control in High Risk Older Adults Post Medicare Part D. *American Heart Journal* 2013 Oct;166(4):792-7.
 110. Bao Y., Ryan A.M., Shao H, Pincus H.A., **Donohue J.M.** Generic initiation and adherence to antidepressant therapy under Medicare Part D. *American Journal of Managed Care*, 2013 Dec;19(12):989-98.
 111. Lo-Ciganic WH, Boudreau RM, Gray SL, Zgibor JC, **Donohue, JM**, Perera S, Newman AB, Simonsick EM, Bauer DC, Satterfield S, Hanlon JT. Changes in cholesterol-lowering medications over a decade in community-dwelling older adults. *Annals of Pharmacotherapy* 47(7-8): 984-92, 2013.
 112. Fowler N.R., Chen Y.F., Thurton C.A., Men A., Rodriguez E.G., **Donohue J.M.** The Impact of Medicare Prescription Drug Coverage on the Use of Antidementia Drugs. *BMC Geriatrics*, 2013 Apr 27;13:37.
 113. Gellad W.F., **Donohue J.M.**, Zhao X., Mor M.K., Thorpe C.T., Smith J, Good C.B., Fine M.J., Morden N.E. Brand-name prescription drug use among diabetes patients in the VA and Medicare Part D: a national comparison. *Annals of Internal Medicine* 2013 Jul 16;159(2):105-1.
 114. Kornfield R., **Donohue J.M.**, Berndt E.R., Alexander G.C. Promotion of prescription drugs to consumers and providers, 2001-2010. *PLOS ONE* March 2013, 8(3).
 115. Gallini A., Huskamp H.A., **Donohue J.M.** Technology diffusion in the antipsychotic market: a comparison of France and the USA between 1998 and 2008. *Psychiatric Services* 2013 Jul 1;64(7):680-7.
 116. Marcum Z.A., Zheng Y., Perera S., Strotmeyer E., Newman A.B., Simonsick E.M., Shorr R.I., Bauer D.C., **Donohue J.M.**, Hanlon J.T. Prevalence and Correlates of Self-Reported Medication Non-Adherence among Older Adults with Coronary Heart Disease, Diabetes Mellitus, and/or Hypertension. *Research in Social and Administrative Pharmacy* 2013 Nov-Dec;9(6):817-27.
 117. Huskamp H.A., O'Malley A.J., Horvitz-Lennon M, Berndt E.R., **Donohue J.M.** How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. *Psychiatric Services* 64(4): 324-330, 2013.

118. Horvitz-Lennon M., **Donohue J.M.**, Lave J.R., Normand S.L. The effect of race/ethnicity on clozapine outcomes among Medicaid beneficiaries with schizophrenia. *Psychiatric Services* 64(3): 230-237, 2013.
119. **Donohue J.M.**, Marcum ZA, Gellad WF, Lave JR, Men A. Hanlon JT. Medicare Part D and Potentially Inappropriate Medication Use in the Elderly *American Journal of Managed Care*, 18(9): e315-22, 2012.
120. Primack BA, Hopkins M, Hallett C, Carroll MV, Zeller M, Dachille K, Kim KH, Fine MJ, **Donohue J.M.** US health policy related to hookah tobacco smoking. *American Journal of Public Health* 102(9): e47-e51, 2012.
121. Dusetzina SB, Busch AB, Conti RM, **Donohue, J.M.**, Alexander GC, Huskamp, HA. Changes in Antipsychotic Use among Patients with Severe Mental Illness after an FDA Advisory. *Pharmacoepidemiology and Drug Safety* 21(12): 1251-60, 2012.
122. Gellad WF, Mor M, Zhao X, **Donohue J.M.**, Good CB. Variation in Use of High-Cost Diabetes Medications in the VA Healthcare System. *JAMA Internal Medicine* 172(20): 1608-1611, 2012.
123. **Donohue J.M.**, Morden N.E., Gellad W.F., Bynum J.P., Zhou W., Hanlon J.T., Skinner J. Sources of regional variation in Medicare Part D drug spending. *New England Journal of Medicine* 366(6): 530-538, 2012.
124. Gellad W.F., Zhao X., **Donohue J.M.**, Banthin J. The financial burden from prescription drugs has declined recently for the non-elderly, although it's still high for many. *Health Affairs* 31(2): 408-416, 2012.
125. Marcum Z.A., Perera S., **Donohue J.M.**, Boudreau R.M., Newman A.B., Ruby C.M., Studenski S.A., Kwoh C.K., Simonsick E.M., Bauer D.C., Satterfield S., Hanlon J.T. Analgesic Use for Knee and Hip Osteoarthritis in Community-Dwelling Elders. *Pain Medicine* Nov;12(11):1628-36, 2011.
126. Gellad W.F., Huskamp H.A., Li A., Safran D., Men A., **Donohue J.M.** Use of Prescription Drug Samples and Patient Assistance Programs, and the Role of Doctor-Patient Communication, *Journal of General Internal Medicine* 26(12): 1458-1464, 2011.
127. Bao Y, Alexopoulos GS, Casalino LP, Ten Have TR, **Donohue J.M.**, Post EP, Schackman BR, Bruce ML. Can Collaborative Depression Care Management Reduce Disparities in Depression Treatment and Outcomes? *Archives of General Psychiatry* Jun; 68(6):627-36, 2011.
128. Polinski J.M., **Donohue J.M.**, Kilabuk E., Shrank W.H. Medicare Part D's impact on the under- and over-use of medications: a systematic review. *Journal of the American Geriatrics Society* Oct;59(10):1922-33, 2011.
129. Lee B.L., Bacon K., **Donohue J.M.**, Wiringa A.E., Bailey R.R., Zimmerman R.K. From the Patient Perspective: the Economic Value of Seasonal and H1N1 Influenza Vaccination *Vaccine*, Mar 3;29(11):2149-58, 2011.
130. Garfield R.L., Zuvekas S.H., Lave J.R., **Donohue J.M.** The impact of national health reform on adults with mental disorders. *American Journal of Psychiatry* 168(5):486-94, 2011.
131. Hanlon J.T., **Donohue J.M.** Medicare Part D Data Will be a Valuable Tool for Pharmacoepidemiology and Pharmacoeconomics Research. (editorial). *American Journal of Geriatric Pharmacotherapy* 8:483, 2010.

132. **Donohue J.M.**, Zhang Y, Men A., Perera S., Lave J.R., Hanlon J.T. Reynolds C.F. Impact of Medicare Part D on Antidepressant Treatment, Medication Choice and Adherence among Older Adults with Depression. *American Journal of Geriatric Psychiatry* 19(12):989-997, 2011. NIHMSID: 244917
133. Zhang Y., **Donohue J.M.**, Lave J.R., Gellad W.F. The Impact of Medicare Part D on Medication Treatment of Hypertension. *Health Services Research* 46(1): 185-198, 2011.
134. Garfield R.L., Lave J.R., **Donohue, J.M.** Health Reform and the Scope of Benefits for Mental Health and Substance Use Services. *Psychiatric Services* 61(11): 1081-1086, 2010.
135. Gellad W.F., Good C.B., Lowe J.C., **Donohue J.M.** Variation in Prescription Spending for Lipid-Lowering and Diabetes Medications in the VA Healthcare System. *American Journal of Managed Care* 16(10):741-750, 2010.
136. **Donohue J.M.**, Zhang Y., Lave J.R., Gellad W.F., Men A., Perera S., Hanlon J.T. The Medicare Drug Benefit (Part D) and Treatment of Heart Failure in Older Adults, *American Heart Journal* 160:159-65, 2010. PMID: PMC2898511
137. Zhang Y., Lee B.L., **Donohue J.M.** Ambulatory Antibiotic Use and Prescription Drug Coverage in Older Adults. *Archives of Internal Medicine* 170(15):1308-14, 2010.
138. Zhang Y, Lave JR, **Donohue J.M.**, Fischer MA, Chernew ME, Newhouse JP. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. *Medical Care* 48(5): 409-417, 2010.
139. Zhang Y., Lave J.R., Newhouse J.P., **Donohue J.M.** How the Medicare Part D Drug Benefit Changed the Distribution of Out-of-Pocket Pharmacy Spending among Older Beneficiaries. *Journal of Gerontology Social Sciences*, 65B(4): 502-507, 2010.
140. Zhang Y., **Donohue J.M.**, Lave J.R., O'Donnell G., Newhouse J.P. The Impact of the Medicare Part D Drug Benefit on Pharmacy and Medical Care Spending. *New England Journal of Medicine* 361: 52-61, 2009.
141. **Donohue J.M.**, Huskamp H.A., Zuvekas S. Dual-eligibles with Mental Disorders and Medicare Part D: how are they faring? *Health Affairs* 28(3): 746-759, 2009.
142. Horvitz-Lennon M.V., **Donohue J.M.**, Domino M., Normand S.L. The Diffusion Paradox in the Care of People with Severe Mental Illnesses. *Health Affairs* 28(3): 701-712, 2009.
143. **Donohue J.M.**, Huskamp H.A., Wilson, I.B. Weissman J. Who do older adults trust to provide information on prescription drugs? *American Journal of Geriatric Pharmacotherapy* 7(2): 105-116, 2009.
144. Zhang Y., **Donohue J.M.**, Newhouse J.P., Lave J.R. The Effects of the Donut Hole on Drug Spending: A Closer Look at Medicare Part D. *Health Affairs* 28, no. 2 (2009): w317-w3125.
145. **Donohue J.M.**, Fischer M., Huskamp H.A., Weissman J. Savings associated with increased use of Consumer Reports Best Buy Drugs. *Health Services Research* 43(5): 1557-1575, 2008.
146. Huskamp HA, **Donohue J.M.**, Berndt ER, Frank RG. Generic Entry, Reformulations, and Promotion of SSRIs. *Pharmacoeconomics* 26(7): 604-616, 2008.
147. **Donohue J.M.**, Cevasco M., Rosenthal M.B. A decade of direct-to-consumer advertising of prescription drugs *New England Journal of Medicine* 357(7): 35-43, 2007.
148. **Donohue J.M.** Frank R.G. The impact of Medicare Part D on Medication Access among Dually Eligible Beneficiaries with mental disorders *Psychiatric Services* 58: 1285-1291, 2007.

149. Huskamp H.A, Stevenson, D.G., **Donohue, J.M.**, Newhouse, J.P., Keating, N.L. Coverage and prior authorization of psychotropic drugs under Medicare Part D. *Psychiatric Services* 58: 308 – 310, 2007.
150. Aspinall S., Sevick M.A., **Donohue J.M.**, Maher R., Hanlon J.T. Medication errors in older adults: a review of recent publications. *American Journal of Geriatric Pharmacotherapy* 5(1): 75-84, 2007.
151. **Donohue J.M.**, Pincus H.A. Reducing the Societal Burden of Depression: A review of economic costs, quality of care and effects of treatment on costs of depression. *Pharmacoeconomics* 25(1): 7-24, 2007.
152. **Donohue, J.M.** Implications of the New Medicare Drug Benefit for Mental Health Treatment. *Psychiatrist Administrator* 6(2): 29-35, 2006.
153. **Donohue J.M.** A history of drug advertising: the evolving roles of consumers and consumer protection. *Milbank Quarterly* 84(4): 659-699, 2006.
154. **Donohue J.M.** Direct-to-Consumer Advertising of Prescription Drugs: Adding to overuse and inappropriate use or alleviating underuse? *International Journal of Pharmaceutical Medicine* 20(1): 17-24, 2006.
155. **Donohue J.M.** Mental Health in the Medicare Drug Benefit: A New Regulatory Model? *Health Affairs* 25(3): 707-719, 2006.
156. **Donohue J.M.**, Hanlon J.T. Helping Medicare patients benefit from the new Medicare drug benefit: an overview with practice tips. *American Journal of Geriatric Cardiology* 14(6): 291-297, 2006.
157. **Donohue J.M.** The Economics of the New Medicare Drug Benefit: Implications for People with Mental Illnesses *Psychiatric Services* 56(6): 645-647, June 2005.
158. **Donohue, J.M.**, and Berndt, E.R. Direct-to-Consumer Advertising and Choice of Antidepressant. *Journal of Public Policy and Marketing*, 23(2): 115-127, 2004.
159. **Donohue J.M.**, Berndt, E.R., Epstein, A.M., Rosenthal, M.B., Frank, R.G. Effects of Pharmaceutical Promotion on Adherence to Guideline Treatment of Depression. *Medical Care* 42(12): 1176-1185, 2004.
160. Rosenthal M.B., Berndt E.R., **Donohue J.M.**, Epstein A.M., Frank R.G. Demand Effects of Recent Changes in Prescription Drug Promotion. *Frontiers in Health Policy Research* 6, 2003.
161. Rosenthal M.B., Berndt E.R., **Donohue J.M.**, Epstein A.M., Frank R.G. Promotion of Prescription Drugs to Consumers. *New England Journal of Medicine* 346(7), 2002.
162. **Donohue J.M.**, and Frank R.G. Medicaid Behavioral Health Carve-Outs: A New Generation of Privatization Decisions. *Harvard Review of Psychiatry* 8, 2000.
163. Barry C.L., and **Donohue J.M.** The Uninsured in the U.S.: An Issue Brief. *Harvard Health Policy Review*, 1(1), Fall 2000.

2. Books and Book Chapters

1. Albert S., and **Donohue J.M.**, “Using epidemiology to inform community health programs and policy” in Anne Newman and Jane Cauley (eds) *Epidemiology of Aging*, New York: Springer, 2013.

2. Berndt E.R. and **Donohue J.M.** “The Economics of Advertising in Health Care Markets” in Frank Sloan and Hirschel Kasper (eds) *Incentives and Choice in Health Care*. Cambridge, MA: MIT Press, 2008.
3. Rosenthal M.B., and **Donohue J.M.** “Direct-to-Consumer Advertising: A Policy Dilemma” in Michael Santoro and Tom Gorrie (Eds.) *Ethics and the Pharmaceutical Industry in the 21st Century*. New York, NY: Cambridge University Press, 2005.

3. Other Publications including Columns and Op-eds

1. National Academies of Sciences, Engineering and Medicine. 2021. *Medications in single dose vials: Implications of discarded drugs*. Washington, DC: the National Academies Press.
2. Miller E, and **Donohue, J.M.** Vaccine distribution should not hold up school reopening. *Pittsburgh Post Gazette* February 14, 2021. Available at <https://www.post-gazette.com/opinion/Op-Ed/2021/02/14/Other-Voices-Vaccine-distribution-should-not-hold-up-school-reopening-Dr-Elizabeth-Miller-and-Julie-M-Donohue/stories/202102140028>
3. **Donohue J.M.** Regulation can make drug ads more useful. *New York Times* Room for Debate, Opinion Pages. December 15, 2013. Available at <http://www.nytimes.com/roomfordebate/2013/12/15/is-the-drug-industry-developing-cures-or-hyping-up-demand/regulation-can-make-drug-ads-more-useful>
4. **Donohue J.M.** Expanding Medicaid would give a boost to Pennsylvania. *Pittsburgh Business Times* July 5, 2013. Available at <http://www.bizjournals.com/pittsburgh/print-edition/2013/07/05/expanding-medicaid-would-give-boost-to.html?page=all>.
5. **Donohue J.M.** Regulation can make drug ads more useful. *New York Times* Room for Debate, Opinion Pages. December 15, 2013. Available at <http://www.nytimes.com/roomfordebate/2013/12/15/is-the-drug-industry-developing-cures-or-hyping-up-demand/regulation-can-make-drug-ads-more-useful>
6. **Donohue J.M.** Berndt ER. Being direct. *Marketing Health Services*. 25(1):30-6, 2005.

4. Web-based Publications

1. Donohue J, Raslevich AC, Cole E. Medicaid’s Role in Improving Substance Use Disorder Treatment. Milbank Memorial Fund Primer. September 25, 2020. <https://www.milbank.org/publications/medicaids-role-in-improving-substance-use-disorder-treatment-in-the-us/>
2. Cunningham P, Woodcock C, Clark M, Middleton A, Barnes A, Idala D, Zhao X, Donohue J. Expanding access to addiction treatment services through Section 1115 Waivers for Substance Use Disorders: Experiences from Virginia and Maryland. *AcademyHealth*. April 2020. https://www.academyhealth.org/sites/default/files/expandingaccesstoaddictiontreatmentthrough1115waivers_april2020.pdf
3. Pennsylvania Department of Health Opioid Data Dashboard. Impacts of the Opioid Epidemic on Families and Children, Related Diseases, and the Economy. Accessed May 29, 2020. <https://data.pa.gov/stories/s/9ium-p8sf>
4. Permanent Supportive Housing and Medicaid Utilization and Spending in Pennsylvania.

Medicaid Research Center. October 2019. Accessed on May 22, 2020.

https://www.dhs.pa.gov/Services/Assistance/Documents/Housing/Housing%20Issue%20Brief%20Final%2010_28_19.pdf

5. Garfield R, **Donohue J**, Cunningham P, Walker L. Issue Brief: Opioid Use Disorder among Medicaid Enrollees: Snapshot of the Epidemic and State Responses. Kaiser Family Foundation, November 15, 2019. <https://www.kff.org/report-section/opioid-use-disorder-among-medicaid-enrollees-snapshot-of-the-epidemic-and-state-responses-issue-brief/>
6. Chalasani R, **Donohue J.M.**, Gellad W.F. Prescription 2020: Democratic Candidates and Drug Pricing. Health Affairs Blog August 29, 2019. <https://www.healthaffairs.org/doi/10.1377/hblog20190826.689286/full/>
7. Rocco P., Gellad W.F, **Donohue J.M.** How much does Congress care about drug prices? Less than it should. Health Affairs Blog January 2016 <http://healthaffairs.org/blog/author/rocco/>
8. **J.M. Donohue.** A plea for more disease awareness ads for antidepressants. Mental Illness Watch <http://www.miwatch.org/>
9. **J.M. Donohue.** “Selection Incentives in the New Medicare Drug Benefit: Implications for People with Mental Illness” Issue paper prepared for TEN Project, May 2005.
10. Frank, R.G., Berndt, E.R., **Donohue, J.M.**, Epstein, A.M., Rosenthal, M.B. “Trends in Direct-to-Consumer Advertising of Prescription Drugs” February 2002. A Henry J. Kaiser Family Foundation publication. <https://doi.org/10.17226/25911>

5. Presentations

Invited, International

1. “Regional Variation in Physician Adoption of Antipsychotics: Implications for Drug and Medical Spending in Medicare.” Twelfth Workshop on Costs and Assessment in Psychiatry - Mental Health Policy and Economics Research: Improving Access, Quality and Outcomes, Venice, Italy March 27-29, 2015
2. “Antipsychotic Prescribing: Do Conflict of Interest Policies Make a Difference?” Twelfth Workshop on Costs and Assessment in Psychiatry - Mental Health Policy and Economics Research: Improving Access, Quality and Outcomes, Venice, Italy March 27-29, 2015
3. “Overview of US pharmaceutical policy and politics” European Market Access Day, Paris, France October 2013.
4. “Changes in antipsychotic prescribing following new evidence.” Eleventh Workshop on Costs and Assessment in Psychiatry,” Mental health policy, economics, and health care reforms. Venice, Italy, March 22-24, 2013.
5. “Implications of National Health Reform for Individuals with Mental Disorders” International Health Economics Association, Toronto, Canada July 11, 2011
6. “Recent changes in US pharmaceutical policy: Medicare Part D, health reform, and beyond.” European Market Access Day, Paris, France December 2010.
7. “Impact of expanding pharmacy benefits on treatment of congestive heart failure: the case of Medicare Part D” International Society of Pharmacoeconomics and Outcomes Research, European Congress, Paris, France, October 24-27 2009.

8. "Use of free medicine samples, doctor-patient communication and cost-related non-adherence among older adults." International Society of Pharmacoeconomics and Outcomes Research, European Congress, Paris, France, October 24-27 2009.

Invited or podium, National

1. "Opioid Use Disorder Policy, Treatment and Outcomes in 12 State Medicaid Programs" Research Panel at AcademyHealth's Annual Research Meeting, June 16, 2021.
2. "Building a Medicaid Policy Laboratory to Address the Opioid Crisis. University of Florida School of Pharmacy, Hartzema Lecture. Grand Rounds Department of Population Health Sciences at Weill Cornell Medicine, April 29, 2021.
3. "Building a Medicaid Policy Laboratory to Address the Opioid Crisis (and other problems). Grand Rounds Department of Population Health Sciences at Weill Cornell Medicine, March 18, 2021.
4. "Using a Distributed Research Network to Evaluate Medicaid Policy Impacts on Opioid Use Disorder Treatment." University of Kentucky Substance Use Research Event, March 3, 2021
5. "Medicaid Outcomes Distributed Research Network: Opioid Use Disorder Project" AcademyHealth, State University Partnership Learning Network Annual Meeting, Washington, DC, December 12, 2019.
6. "Changes in Medicaid Prior Authorization for Medications for Opioid Use Disorder (MOUD): Implications for Treatment. Urban Institute. Washington DC, December 11, 2019.
7. "Research collaboration with states – opportunities to shape addiction treatment systems" (panelist) Addiction Health Services Research, Park City, UT, October 18, 2019
8. "Quality of opioid use disorder treatment in 8 state Medicaid programs" Addiction Health Services Research, Park City, UT, October 20, 2019
9. "Medicaid Outcomes Distributed Research Network (MODRN): Evaluating Medicaid policies to address the opioid crisis" AcademyHealth Annual Research Meeting, Washington DC, June 3, 2019.
10. "Securing the Safety Net: University-State Partnerships to Inform Medicaid policy" West Virginia University School of Public Health Dean's Colloquium. Morgantown, WV, March 2019.
11. "Overview and Findings from the Medicaid Outcomes Distributed Research Network (MODRN). AcademyHealth State University Partnership Learning Network, Washington DC, November 29, 2018.
12. "Examining the quality of opioid use disorder treatment in a Medicaid research network." AcademyHealth Medicaid Medical Directors Network Fall Workshop, Washington DC, November 1, 2018.
13. "Medicaid prior authorization and opioid medication abuse and overdose" Association for Public Policy and Management Chicago, IL November 2017.
14. "Effects of Global Payment and Accountable Care on Medication-Assisted Treatment for Alcohol and Opioid Use Disorders." International Health Economics Association Boston, MA, July 2017.

15. "Social network analysis of physician adoption of new prescription drugs." Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Safety, Value and Innovation Seminar Series, Baltimore, MD May 8, 2017.
16. "Identifying and treating opioid addiction in Pennsylvania Medicaid" University of Pennsylvania School of Medicine Center for Clinical Epidemiology and Biostatistics Seminar Series March 30, 2017.
17. "Pennsylvania's response to opioid crisis: Identifying risk factors for overdose and reforming the delivery system" Academy Health's State-University Partnership Learning Network, Washington DC, November 17, 2016.
18. "State-University Partnerships: Generating Evidence to Support State Policymaking" Association for Public Policy Analysis and Management, Washington DC, November 3, 2016.
19. "Medicare and Medicaid prescription drug programs: Can they survive in the long-run? Coit Lecture, University of Arizona College of Pharmacy. Tucson, AZ, October 20, 2016
20. "Social network analysis of physician adoption of new prescription drugs" University of Arizona College of Pharmacy Doctoral Student Research Seminar, October 19, 2016
21. "Payer strategies to address the Opioid Crisis: Prevention and Treatment" National Academy for State Health Policy. Pittsburgh, PA October 17, 2016.
22. "Effects of Global Payment and Accountable Care on Medication-Assisted Treatment for Alcohol and Opioid Use Disorders" Addiction Health Services Research Meeting. Seattle, WA, October 14, 2016.
23. "Medication use in the Marketplace: An early view on the health status of enrollees." Academy Health, Annual Research Meeting, Minneapolis, June 2015.
24. "Understanding regional variation in use of prescription drugs." Pennsylvania State University Health Policy and Administration Colloquium, April 2013.
25. "US physician prescribing practices in the 21st century: a case study of antipsychotics" RAND Health Seminar May 2012.
26. "Impact of Medicare Part D on racial differences in diabetes treatment and outcomes in older adults." Gerontological Society of America, Boston, MA November 2011, poster presentation.
27. "What drives regional variation in Medicare Part D drug spending?" Gerontological Society of America, Boston, MA November 2011, poster presentation.
28. "Cost-effectiveness of bypassing the blues" National Institute of Mental Health, Mental Health Services Research Meeting, Washington DC, July 27, 2011
29. "Physician responses to comparative effectiveness research: the case of atypical antipsychotics." National Institute of Mental Health, Mental Health Services Research Meeting, Washington DC, July 27, 2011
30. "Will Reducing Variation in Hospitalization Bend the Medicare Cost Curve? If so, where do we start?" Academy Health, Boston, MA June 2010.
31. "Medicare Part D's Impact on Use of High Risk Medications among Older Adults." Academy Health, Boston, MA June 2010.
32. "Impact of Medicare Part D Cost-Sharing on Medication Use among Dual Eligibles with Mental Disorders." American Society of Health Economists, Ithaca, NY June 2010

33. "Impact of Expanded Health Insurance Coverage on Individuals with Mental Illnesses and Substance Use Disorders," Expert Panel Meeting, U.S. Department of Health and Human Services, April 8, 2010
34. "Medicare Part D: an overview of economics, regulation and early evidence of impact." Drug Information Association annual conference, Boston, MA, June 25, 2008.
35. "Medicare Part D's impact on utilization and expenditures for antidepressants." American Society of Health Economists, Durham, NC, June 22-24, 2008.
36. "Medicare Part D's Impact on treatment patterns and health outcomes for depression." Centers for Medicare and Medicaid Services, Part D Research Forum, Baltimore MD, June 11, 2008.
37. "Impact of Medicare Part D on treatment of depression among the elderly." Academy Health Annual Research Meeting, Washington DC, June 8-10, 2008.
38. "Impact of Medicare Part D on medication and health services use among beneficiaries with depression." The Dartmouth Institute for Health Policy and Clinical Practice. Lebanon, NH, May 9, 2008.
39. "Medication access for dually eligible beneficiaries with mental disorders under Medicare Part D," Biennial National Institute of Mental Health Conference on Mental Health Economics, Bethesda, MD, September 2006
40. "Economics of Direct-to-consumer advertising of prescription drugs" Incentives and Choice in Health Care Conference at Oberlin College, in Oberlin, OH, September 2006.
41. "Doctor patient communication about prescription drug costs," Poster NIH Multidisciplinary Clinical Research Scholars Program" Bethesda, MD March 2007
42. "Medication Access for Dual Eligibles with Mental Disorders Under Medicare Part D," poster, Academy Health Seattle, WA June 2006
43. "Economic Impact of the Consumer Reports Best Buy Drugs Program," poster, Academy Health, Seattle, WA, June 2006
44. "Savings associated with increased use of Consumer Reports Best Buy Drugs," podium presentation, Society of General Internal Medicine, April 27, 2006, Los Angeles, CA.
45. "If we increased use of Consumer Reports Best Buy Drugs how much would we save?" podium presentation, Consumer Reports Best Buy Drugs Program Symposium, March 2-3, 2006, Washington, D.C.
46. "Pharmacy Benefit Management and Mental Health: Medicare Part D and Beyond" podium presentation, Robert Wood Johnson Foundation Program on Depression and Primary Care, Annual Meeting February 17, 2006, Amelia Island, FL.
47. "Transitioning Dually Eligible Individuals with Mental Disorders to Medicare Part D: Estimating the Effects on Access to Care," podium presentation, National Institute of Mental Health Research Coordination Workshop on the Medicare Modernization Act, Bethesda MD, December 2005.
48. "Formulary Design in the New Medicare Drug Benefit," podium presentation, National Institute of Mental Health Pharmacoeconomics Workshop, Bethesda MD, May 2005.

49. “The New Medicare Drug Benefit: Implications for Depression Treatment,” podium presentation, *Depression in Primary Care: Linking Clinical and Systems Strategies*, Annual Program Meeting, November 2004.
50. “Demand Effects of Direct-to-Consumer Advertising,” podium presentation, *Achieving DTC Success* conference sponsored by DTC Perspectives, Princeton, NJ, October 15-16, 2003.
51. “Effects of Direct-to-Consumer Advertising of Prescription Drugs on the Treatment of Depression,” podium presentation, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, public meeting on *Research on Consumer Directed Advertising*, Washington, D.C., September 22-23, 2003.

Local or regional

1. “Risk of long-term opioid use and its sequelae due to opioid prescribing for acute pain” Challenges in Managing and Preventing Pain (CHAMPP) Research Seminar, March 2021.
2. “Social network analysis of physician adoption of new prescription drugs” HPM Seminar January 2019.
3. “Policy challenges in expanding access to opioid addiction treatment” Center for Bioethics and Health Law Annual Conference, University of Pittsburgh, March 2018
4. “Anatomy of inpatient opioid prescribing (and consequences for continued use post-discharge) Center for Research on Health Care September 2018.
5. “Building blocks and benefits of a Medicaid Distributed Research Network” Medicaid Research Seminar July 2018.
6. “Treatment of opioid use disorder in Pennsylvania Medicaid: a comparison with neighboring states” Pennsylvania Opioid Command Center, Harrisburg, PA June 2019
7. “What observational studies can (and cannot) tell us about the opioid crisis” Public Health Dynamics Laboratory, University of Pittsburgh, March 2018.
8. “Pharmaceutical prices in the US: why are they high and what do we do about it? University of Pittsburgh School of Medicine December 2017
9. “Policy challenges in expanding access to opioid addiction treatment” Center for Bioethics and Health Law Annual Conference, University of Pittsburgh, March 2018
10. “What observational studies can (and cannot) tell us about the opioid crisis” Public Health Dynamics Laboratory Seminar, University of Pittsburgh March 2018
11. “After the House Vote: The Road Ahead for the ACA” University of Pittsburgh School of Medicine, May 2017
12. “Affordable Care Act: Past, Present, Future” for University of Pittsburgh Pre-Health Student Coalition May 2017
13. “From Obamacare to Trumpcare” University of Pittsburgh Graduate School of Public Health Food for Thought Series April 2017.
14. “Repeal, repair or replace? The future of the Affordable Care Act” University of Pittsburgh Current Issues Forum March 16, 2017.

15. “The Future of the Affordable Care Act” University of Pittsburgh Medical Student Training Program. December 7, 2016.
16. “Who’s at risk for prescription opioid overdose and how can health systems respond? Center for Research on Health Care Health Services Research Seminar, February 2016.
17. “The Affordable Care Act” Allegheny Chesapeake Physical Therapy, July 2014.
18. “Who signed up for coverage under the Affordable Care Act?” Department of Medicine, University of Pittsburgh, Grand Rounds May 2015.
19. “The Affordable Care Act: A Work in Progress” Lecture for the Departments of Neurology, Neurosurgery and Critical Care Medicine, University of Pittsburgh School of Medicine, May 2014.
20. “The Affordable Care Act” Allegheny Chesapeake Physical Therapy, July 2013.
21. “From RomneyCare to ObamaCare: problems and progress in reforming US health care” Department of Critical Care Medicine Grand Rounds, September 2012, Pittsburgh, PA
22. “US Health Care Reform” Minute Men of Pittsburgh, Pittsburgh PA November 2012.
23. “Pipeline, payment, and promotion: recent changes in US pharmaceuticals” University of Pittsburgh Bioinformatics Colloquium February 2012.
24. “A primer on health care financing and economics.” Pediatric Critical Care Clinical Division, Children’s Hospital Pittsburgh December 2011.
25. “Fitting into the global picture: how do other countries control costs?” Messer Conference, Center for Bioethics and Health Law, University of Pittsburgh.
26. “Health Reform 2010: Overview and Implications for Physicians” University of Pittsburgh Department of Medicine Administrative Retreat, May 25, 2010.
27. “Impact of Medicare Part D” Department of Epidemiology, Center for Aging and Population Health, May 4, 2010.
28. “Update on health reform” Albert Schweitzer Fellowship Program, Pittsburgh, PA March 21, 2010.
29. “Pharmacogenetics and mental health” Multidisciplinary Mental Health Services Research Seminar. Department of Psychiatry. December 14, 2009.
30. Medicare Part D” Geriatric Research Education and Clinical Centers, VA Pittsburgh Health Care System, December 2009.
31. “Pharmacogenomics and Mental Health” University of Pittsburgh Department of Psychiatry, Mental Health Services Research Seminar November 18, 2009.
32. “Update on National Health Reform” Department of Health Policy and Management, Health Policy Seminar, September 14, 2009.
33. “Medicare Part D’s Effect on the Health of Older Americans” RAND Health Policy Seminar, July 6, 2010.
34. “Medicare Part D’s Effects on the Health of Older Americans” Senior Vice Chancellor’s Research Seminar, May 1, 2009.
35. “Trends in the U.S. Pharmaceutical Industry: Implications for New Drug Development,” University of Pittsburgh Drug Discovery Institute, January 28, 2009.

36. “Optimizing insurance benefit design: the case of Medicare Part D.” Presentation to the External Advisory Committee to the University of Pittsburgh, Clinical and Translational Science Institute. March 2008.
37. “Improving quality of primary care for anxiety disorders: Part 3, a non-inferiority and cost-effectiveness trial of telephone vs. internet-based stepped collaborative care.” Multidisciplinary Mental Health Services Research Seminar, Department of Psychiatry. February 7, 2008.
38. “Impact of Medicare Part D on racial disparities in treatment and outcomes for diabetes.” Health Services Research Development Seminar, Center for Research on Health Care. December 5, 2007.
39. “Direct-to-consumer advertising of prescription drugs.” Graduate School of Public Health Board of Visitors Meeting, November 30, 2007.
40. “Universal Health Care: the political perspective” Panel presentation University of Pittsburgh School of Medicine.
41. “Doctor-patient communication about prescription drug costs” University of Pittsburgh, Center for Research on Health Care Health Services Research Seminar April 10, 2007.
42. “Generic Entry, New Formulations and Pharmaceutical Promotion” Monthly Modeling Meeting, Center for Research on Health Care, University of Pittsburgh, April 10, 2007.
43. “Direct-to-Consumer Advertising and Medical Consumerism” Center for Bioethics and Health Law Grand Rounds, University of Pittsburgh, December 2005.
44. “Effects of Direct-to-Consumer Advertising on Medication Choice: the Case of Antidepressants” Marketing Brown Bag Seminar Series, Katz Graduate School of Business, University of Pittsburgh, April 2005.
45. “The New Medicare Drug Benefit: Implications for People with Mental Illnesses” Center for Research on Health Care, Research Development Seminar, April 2005.
46. “Direct-to-Consumer Advertising and the Treatment of Depression,” *Health Services Research Seminar* Sponsored by the Center for Research on Health Care, University of Pittsburgh, October 2004.

6. Select Reports for State Agencies

1. **Donohue JM**, Li J, Sharbaugh M, Xue L, Cole E. Risk Factors for Severe Cases of COVID-19 in PA Medicaid, and Potential Post-Acute Care Needs. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2020.
2. O’Connor J, Cole E, Jarlenski M, **Donohue JM**. Pennsylvania Medicaid Enrollment Projections Through the COVID-19 Pandemic. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2020.
3. Khouja T, Yabes J, Moore P, Weyant R, **Donohue JM**. Initial Opioid Prescribing and Subsequent Opioid Use After Dental Procedures Among Opioid Naïve Patients in Pennsylvania Medicaid, 2012-2017, Medicaid Research Center report for Pennsylvania Department of Human Services, January 2020.
4. **Donohue JM**, O’Connor J, Xue L, Cole E. Analytic Plans and Results for Baseline Measures for a Value-Based Payment Model: Center of Excellence (COE) Programs in Pennsylvania.

- Medicaid Research Center report for Pennsylvania Department of Human Services, January 2020.
5. Sabik L, Eom K, Schoen RE, Jarlenski M, Cole E, **Donohue JM**, Sun Zhaojun. Costs Associated with Colorectal Cancer Testing in Pennsylvania. Medicaid Research Center report for Pennsylvania Department of Human Services, January 2020.
 6. Hollander M, Cole E, Roberts E, **Donohue JM**. Permanent Supportive Housing: Physical and Behavioral Health Spending in the Pretreatment period. Medicaid Research Center report for Pennsylvania Department of Human Services, January 2020.
 7. Cole E, Li J, **Donohue JM**. Provider-Level Medications for Opioid Use Disorder (MOUD) Prescribing Measures. Medicaid Research Center report for Pennsylvania Department of Human Services, February 2020.
 8. Cole E, Xue L, **Donohue JM**. Opioid Use Disorder Treatment for Pennsylvania Medicaid Enrollees. Medicaid Research Center report for Pennsylvania Department of Human Services, October 2019
 9. O'Connor J, Cole E, **Donohue JM**, Sharbaugh M, Kim JY, Pringle J, Wang R, Derringer C, Ethun L. Pennsylvania Centers of Excellence Evaluation: Interim Report. Medicaid Research Center report for Pennsylvania Department of Human Services, December 2019.
 10. Hollander M, Cole E, Roberts E, **Donohue JM**. Permanent Supportive Housing and Medicaid Utilization and Spending in Pennsylvania: Sub-Analysis of Medicaid Spending After Exit from Permanent Supportive Housing. Medicaid Research Center report for Pennsylvania Department of Human Services, September 2019.
 11. Krans EE, Rothenberger S, Kelley D, **Donohue JM**, Jarlenski M. Medication Treatment for Opioid Use Disorder and Maternal and Child Health Outcomes. Medicaid Research Center report for Pennsylvania Department of Human Services, September 2019.
 12. O'Connor J, Cole E, **Donohue JM**, Fay E, Ethun L, Mirigian L, Pringle J. Centers of Excellence and Opioid Abuse in Pennsylvania: Demographic and Health Profile Analysis. Medicaid Research Center report for Pennsylvania Department of Human Services, June 2019.
 13. Cole E, Roberts E, Hollander M, **Donohue JM**, Sowers W, Li J, Kim JY, Ennis M, Qi C, DaCosta. Pennsylvania Supportive Housing and Medicaid Utilization and Spending in Pennsylvania: Matched Comparison Analysis. Medicaid Research Center report for Pennsylvania Department of Human Services, May 2019.
 14. Sabik L, Eom K, Schoen RE, Jarlenski M, Cole E, **Donohue JM**, Sun Z. Colorectal Cancer Prevalence and Screening in Pennsylvania Medicaid. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2019.
 15. Jarlenski M, Krans EE, **Donohue JM**, James AE, Kelley D, Rothenberger S, Stein BD, Bogen DL. Healthcare Utilization and Pediatric Chronic Conditions in the First Five Years Among Children with In-Utero Opioid Exposure. Medicaid Research Center report for Pennsylvania Department of Human Services, March 2019.
 16. Ennis M, Cole E, **Donohue JM**, Roberts E, James E, Costlow M. Medicaid Authorities to Cover Supportive Housing Services. Medicaid Research Center report for Pennsylvania Department of Human Services, January 2019.
 17. O'Connor J, Ennis M, Cole E, **Donohue JM**. Lead abatement and Medicaid savings: review of the literature. Medicaid Research Center report for Pennsylvania Department of Human

- Services, January 2019.
18. Gellad WF, Cole E, **Donohue JM**, Men A, Kim JY, Metes I. Medication Adherence Among Pennsylvania Medicaid Enrollees: Medical and Drug Expenditure Modeling. Medicaid Research Center report for Pennsylvania Department of Human Services, September 2018.
 19. Cole E, Ennis M, **Donohue JM**, James AE. Cost-Containment Policy Options for Pennsylvania Medicaid. Medicaid Research Center report for Pennsylvania Department of Human Services, August 2018.
 20. Cole E, Roberts E, Men A, **Donohue JM**, Sowers W, Kim JY, Ennis M, DaCosta D, Permanent Supportive Housing and Medicaid Utilization and Spending in Pennsylvania: Demographic and Health Profile Analysis. Medicaid Research Center report for Pennsylvania Department of Human Services, 2018.
 21. Cole E, **Donohue JM**, Chang CCH, Fusco R, Sharbaugh M, Raslevich A. Office of Developmental Programs Inspection Decision Support. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2018.
 22. Gellad WF, Cole E, **Donohue JM**, Sabik L, Lo-Ciganic WH, Men A, Kim JY, Metes I. Medication Adherence Among Pennsylvania Medicaid Enrollees. Medicaid Research Center report for Pennsylvania Department of Human Services, August 2017.
 23. Sabik L, Driessen J, Cole E, **Donohue JM**, Kahn J, Men A. Emergency Department Utilization Among the Pennsylvania Medicaid Expansion Population. Medicaid Research Center report for Pennsylvania Department of Human Services, July 2017.
 24. Driessen J, Cole E, Jarlenski M, Sabik L, **Donohue JM**. Preliminary Analysis of the Impact of Per Capita Caps for Pennsylvania Medicaid. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2017.
 25. Cole E, **Donohue JM**, Hollander M. Low-Value Services in Pennsylvania Medicaid 2013-2015. Medicaid Research Center report for Pennsylvania Department of Human Services, April 2017.
 26. **Donohue JM**, Cole E, Kim JY, Zheng P, Lo-Ciganic W-H. Report on Opioid Prescribing Quality Measures, Opioid Use, Opioid Use Disorder, and Medication-Assisted Treatment in Pennsylvania Medicaid: 2013-2015. Medicaid Research Center report for Pennsylvania Department of Human Services, March 2017.
 27. Cole E, **Donohue JM**, Hollander M, Gopalan K. Trends in Medicaid Behavioral Health Policies. Medicaid Research Center report for Pennsylvania Department of Human Services, February 2017.
 28. Cole E, **Donohue JM**, Hughes M. Health Homes for Medicaid Beneficiaries: Federal Financing For Opioid Use Disorder Centers of Excellence. Medicaid Research Center report for Pennsylvania Department of Human Services, October 2016.
 29. **Donohue JM**, Frazier W, Lo-Ciganic W-H, Kim JY, Zheng P, Cochran G, Gellad WF. Opioid Use Disorder in Pennsylvania Medicaid: Understanding Treatment Patterns Pre- and Post-Overdose and Buprenorphine Prescribing Behavior. Medicaid Research Center report for Pennsylvania Department of Human Services, May 2016.
 30. Gellad WF, Kabiri M, Chhatwal J, Dunn MA, **Donohue JM**, Roberts MS. Hepatitis C Prevalence and Costs in Pennsylvania Medicaid. Medicaid Research Center report for

Pennsylvania Department of Human Services, August 2015.

31. Kahn JM, Le TQ, **Donohue JM**. Pediatric Home Nursing Utilization in Pennsylvania Medicaid. Medicaid Research Center report for Pennsylvania Department of Human Services, June 2014.
32. **Donohue JM**, Lo-Ciganic W-H, Cochran G, Gordon AJ, Zemaitis MA, Gellad WF. Report on Opioid use, Opioid Use Disorder and Buprenorphine Use in Pennsylvania Medicaid. Medicaid Research Center report for Pennsylvania Department of Human Services, March 2014
33. Price C., **Donohue, J.M.**, Saltzman E., Woods D., Eibner C. Economic impact of Medicaid expansion on Pennsylvania. Report for the Hospital and Health System Association of Pennsylvania. March 2013.
34. **Donohue, J.M.**, Garfield R., Lave J.R. “The impact of expanded health insurance coverage on individuals with mental illnesses and substance use disorders” Report prepared for Mathematica Policy Research, Inc. and the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, March 2010.
35. Frank, R.G., Berndt, E.R., **Donohue, J.M.**, Rosenthal, M.B. “Determinants and Effects of Direct to Consumer Advertising of Prescription Drugs: A Research Agenda.” A background report prepared for the Department of Health and Human Services conference, *Assessing the Impact of Direct-to-Consumer Advertising on Health Care Use, Costs and Outcomes*, April 2001.
36. **Donohue, J.D.** “E-Health: Providers, Patients and the Web.” Policy Brief for Harvard University, Kennedy School of Government/Commonwealth Fund Bipartisan Congressional Health Policy Conference, January 2001.
37. **Donohue, J.D.** “Medical Safety: Putting into Practice What We Know.” Policy Brief for Harvard University, Kennedy School of Government/Commonwealth Fund Bipartisan Congressional Health Policy Conference, January 2001.
38. **Donohue, J.D.** “Health Insurance: Are Employers the Solution?” Policy Brief for Harvard University, Kennedy School of Government/Commonwealth Fund Bipartisan Congressional Health Policy Conference, January 2001.
39. **Donohue, J.D.** “Rural Health Care: Dilemmas, Access, and Providers.” Policy Brief for Harvard University, Kennedy School of Government/Commonwealth Fund Bipartisan Congressional Health Policy Conference, January 2001.
40. **Donohue, J.D.**, Hanson, K.W., Huskamp, H.A. “Persons with Disabilities and Medicaid Managed Care: Issues in Programmatic Design, Enrollment, Procurement, and Contracting.” Report prepared for the Center for Health Care Strategies, Inc., and the Robert Wood Johnson Foundation. November 1999.

SERVICE **(Professionally related)**

1. University/Institute of higher learning

Years	Committee	Position
2016-2017	Search committee for Chief of Division of General Internal Medicine, School of Medicine	Member
2009-2012	Health Services Research Seminar Series	Co-director
2010-2012	Public Health and Aging Seminar Series	Director
2005 – 2011	Graduate School of Public Health, Planning, Budget and Policy Committee	Member
2005 – 2011	Health Policy and Management Masters Programs	Member
2006 – present	Admissions Committee	
2008	Department of Health Policy and Management, Ph.D. in Health Services Research and Policy, faculty committee	Member
2008-present	Search committee, HPM department chair	Member
	Search committee, HPM faculty member recruitment for health economics, health policy, management and other positions	Member

2. Service to Field of Scholarship

a. Editorial Boards, Editorships

Date	Position	Organization
2020-	Associate Editor	<i>JAMA Health Forum</i>
2010-18	Editorial Consultant	<i>Psychiatric Services</i> , a journal of the American Psychiatric Association

b. Manuscripts and other document/publication review

Ad hoc reviewer

Dates	Journal Title
2006-	<i>American Journal of Geriatric Pharmacotherapy</i>
2004-	<i>American Journal of Managed Care</i>
2019-	<i>American Journal of Preventive Medicine</i>
2011-	<i>American Journal of Psychiatry</i>
2008-	<i>Archives of General Psychiatry</i>

Dates	Journal Title
2012-	<i>Circulation</i>
2005-	<i>Drugs and Aging</i>
2008-	<i>Expert Review of Pharmacoeconomics and Outcomes Research</i>
2007-	<i>Gerontologist</i>
2005-	<i>Health Affairs</i>
2006-	<i>Health Economics</i>
2006-	<i>Inquiry</i>
2010	<i>International Journal of Management Reviews</i>
2009-	<i>Journal of Affective Disorders</i>
2005-	<i>Journal of Aging and Social Policy</i>
2010-	<i>Journal of the American Geriatrics Society</i>
2008-	<i>Journal of Applied Gerontology</i>
2004-	<i>Journal of Behavioral Health Services Research</i>
2005-	<i>Journal of Clinical Psychiatry</i>
2005-	<i>Journal of General Internal Medicine</i>
2006-	<i>Journal of Health Care for the Poor and Underserved</i>
2007-	<i>Journal of Health Politics Policy and Law</i>
2005-	<i>Journal of Health Economics</i>
2008-	<i>Journal of Law and Medical Ethics</i>
2007-	<i>Journal of Mental Health Policy and Economics</i>
2007-	<i>Journal of Political Economy</i>
2006-	<i>JAMA</i>
2007-	<i>JAMA Internal Medicine</i>
2008-	<i>Managed Care Interface</i>
2005-	<i>Medical Care</i>
2007-	<i>Milbank Quarterly</i>
2009-	<i>Nature Biotechnology</i>
2008-	<i>New England Journal of Medicine</i>
2007-	<i>Pharmacoeconomics</i>
2006-	<i>Psychiatric Services</i>
2005-	<i>Psychological Medicine</i>
2006-	<i>Social Science and Medicine</i>
2011-	<i>Southern Economic Journal</i>
2006-	<i>Value in Health</i>

c. Study Sections, Review Panels, and Advisory Boards

Date	Position	Organization
December 2019- March 2021	Committee Member	National Academies of Sciences, Engineering, and Medicine Committee on Implications of Discarded Weight-Based Drugs
May 2020-	Advisory Board Member	The Roybal Center for Therapeutic Optimization Using Behavioral Science, Brigham and Women's Hospital
March 2021	Ad hoc reviewer	National Institutes of Health
March 2019	Ad hoc reviewer	National Institutes of Health
March 2018	Ad hoc Reviewer	National Institutes of Health
July 2014	Ad hoc Reviewer	National Institute on Aging
May 2014	Ad hoc Reviewer	National Institutes of Health
September 2013	Grant Reviewer	Robert Wood Johnson Foundation
March 2010	Grant Reviewer	University of Pittsburgh Department of Psychiatry RAND University of Pittsburgh Health Initiative
June 2008	Grant Reviewer	Pilot Grant Program
April 2008	Advisor	Planning meeting for <i>Health Affairs</i> special issue on mental health policy
May 2007	Grant Reviewer	Israel National Institute for Health Policy and Health Services Research

d. Leadership in Professional Organizations and Societies

Date	Position	Organization
2008-2011	Secretary and Treasurer	Health Sciences Section, Gerontological Society of America
2006-2009	Member Public Policy Committee	Gerontological Society of America
2007, 2008	Abstract review panel member for Behavioral Health Section	Academy Health

e. Consultantships

- 2011 National Railways Labor Conference
- 2010 Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services; Mathematica Policy Research
- 2008 Expert witness for Attorney General of Massachusetts in Medicaid prescription drug pricing fraud case against 7 pharmaceutical manufacturers. Gave a tutorial to U.S. District Court Judge Patti Saris
- 2006-2008 Expert witness for Canadian Supreme Court case on direct-to-consumer advertising of prescription drugs
- 2006 Litigation consulting on direct-to-consumer advertising for GlaxoSmithKline on a transfer pricing case